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ABSTRACT 
A Tn7-based transposition system carrying a kanamycin resistance gene has been 
used to disrupt a known virulence gene of Brucella melitensis 16M and Brucella abortus 
2308 in-vitro.  The suicide plasmid pBAvirB1::kan-29 was created, in part, by cloning the 
B. abortus virB1 gene into a vector that is not stably maintained in Brucella spp.  The 
cloned virB1 gene was then mutagenized by in-vitro transposition of a Tn7-based 
transposon.  This construct was used in-vivo to insert a disrupted virB1 gene in place of 
the wild type virB1 found in B. abortus 2308 and B. melitensis 16M by homologous 
recombination.  The resulting virB1 mutant brucellae exhibited resistance to kanamycin, 
decreased survival in murine macrophages and attenuated virulence in a BALB/c mouse 
model.  This method is proposed to be a simple, efficient means of generating gene 
knockouts in Brucella spp., and may be useful in targeting virulence factors for the 
creation of live, attenuated vaccines.  The genus Brucella consists of bacteria that are 
facultative intracellular pathogens.  Individuals in this genus of Gram-negative 
coccobacilli are responsible for causing late term spontaneous abortion in cattle and goats 
as well as the human disease brucellosis (undulant fever).  The success of Brucella is 
dependent on their ability to invade, survive and multiply within phagocytes.  The virB 
operon, consisting of eleven genes in most Brucella species, is thought to contribute to a 
type IV secretion system responsible for maintaining infection in a mammalian host.  
Further results of this study suggest that the Brucella virB1 gene product, like its 
Agrobacterium counterpart, may not be essential for virulence; disruption of the Brucella 
virB1 gene results in a one to two log decrease in intracellular survival at forty-eight 
hours in an in-vitro macrophage model and by four weeks in an in-vivo mouse model. 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
During the late nineteenth century a German physician named Robert Koch set 
out to prove the germ theory of disease, which had been stated by Girolamo Fracastoro of 
Verona over three hundred years earlier.  From his studies with anthrax, Koch formulated 
a set of postulates that are still used today for the identification of etiological agents 
(Atlas 1997).  With the connection between microorganisms and disease established there 
came an understanding of vaccination, the discovery of antimicrobial agents and the 
study of virology and immunology.  As a result of these and other technological 
advances, the average human life expectancy rose dramatically and once common 
ailments such as measles, diphtheria, pneumonia and tuberculosis became treatable and 
sometimes curable.  One such treatable disease of humans and a wide variety of 
mammals is brucellosis, which is caused by bacteria of the genus Brucella.   
While stationed on the island of Malta, the British army physician, David Bruce, 
was the first to successfully isolate and culture Micrococcus melitensis in 1897, which 
was later renamed Brucella melitensis in his honor (Spink 1956; Dalrymple-Champneys 
1960).  As many British sailors discovered, Brucella infection may lead to the 
debilitating, chronic disease known as brucellosis.  If it is not treated with antibiotics, 
brucellosis can result in lymphoid organ inflammation together with bone and joint 
problems, and in rare cases death (Spink 1956; Dalrymple-Champneys 1960; Thimm 
1982; FAO/WHO 1986; Jawetz, Melnick et al. 1989; Madkour 1989; Paul 1993; Young 
1995; Comerci, Martinez-Lorenzo et al. 2001; DelVecchio, Kapatral et al. 2002).   
Brucella is also responsible for late-term abortion in several domestic and wild 
mammals, including swine, goats, cattle, sheep, bison and elk (Spink 1956; Dalrymple-
Champneys 1960; WHO/EMC 1998).  Although the incidence of Brucella infection has 
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been greatly reduced or eliminated in many countries, brucellosis is still the world’s most 
widespread zoonoses and is prevalent in many underdeveloped nations (Ruben, Band et 
al. 1991).  Of additional importance is the designation of Brucella as a biosafety level III 
disease organism and its use as an agent of biological warfare.  According to the Centers 
for Disease Control and Prevention (CDC) in Atlanta, which considers Brucella a select 
agent with Class B status as a biological threat (same category as the agents which cause 
Q fever and encephalitis), brucellae are listed among the top ten most important 
biological warfare agents for public health preparedness (Frederick, Takafuji et al. 1997; 
Rotz, Khan et al. 2002).  Outlined in a report by the WHO in 1970 (Health Aspects of 
Chemical and Biological Weapons), it was calculated that upon biological attack, 
brucellae have the potential to incapacitate as many people as an equivalent dose of 
Bacillus anthracis or Coxiella burnetii (causative agent of Q fever) (as reviewed by 
Christopher, Cieslak et al. 1997; Madigan, Martinko et al. 2000).  But while vaccines 
have been developed to protect against other biological diseases such as tularemia, Q 
fever and anthrax, a Brucella vaccine has been illusive, being unsuitable for human use 
(Huxsoll et al. 1989 as cited in Franz, Parrot et al. 1997). 
1.1 General Characteristics of Brucella spp. 
 Brucellae are small, non-motile, Gram-negative coccobacilli about 0.6µm - 1.5µm 
in length and 0.5µm - 0.7µm in width, found in the α2 subdivision of the phylum 
Proteobacteria (Thimm 1982; FAO/WHO 1986; Moreno, Stackebrandt et al. 1990).  The 
majority of species in this subdivision are associated with eukaryotes as endosymbionts 
or pathogens (Fig. 1) (Ugalde 1999; Sieira, Comerci et al. 2000).  Individuals in the 
genus Brucella are intracellular pathogens of mammals including humans (Dalrymple-
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Champneys 1960).  All species of Brucella are non-spore forming and aerobic, except for 
B. abortus and B. ovis, which are carboxyphilic, requiring an increased CO2 tension of 
5% for optimal growth (Thimm 1982; FAO/WHO 1986; Thoen, Enright et al. 1993).     
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Partial phylogenetic tree of the α-2 subgroup of Proteobacteria with the addition 
of Rhodobacter (α-3 subgroup) (redrawn from Jumas-Bilak, Michaux-Charachon et 
al. 1998b). 
 
Brucellae are currently categorized into at least six different species 
encompassing 18 biovars, with several undesignated strains that infect marine mammals 
(Bricker 2000; Moreno and Moriyon 2002). There is evidence, however, to suggest that 
the genus is monospecific with B. melitensis considered the type species (Verger, 
Grimont et al. 1985; Michaux-Charachon, Bourg et al. 1997).  Each species is specialized 
to an existence within a particular mammal host:  B. abortus in cattle, bison and elk; B. 
Agrobacterium vitis 
A. rubi 
Rhizobium 
leguminosarum 
A. tumefaciens 
A. rhizogenes 
Phyllobacterium 
myrsinacearum 
Bartonella quintana
Mycoplana 
dimorpha 
Ochrobactrum anthropi 
Brucella spp. 
Rhodobacter sphaeroides
Rhodobacter 
capsulatus
Bradyrhizobium japonicum
beta and gamma Rhizobium 
fredii
Rhizobium. meliloti 
 4
melitensis in goats and sheep; B. suis in pigs; B. canis in dogs; B. ovis in sheep and B. 
neotomae has been found in the desert wood rat (W. Wundt 1956 and FAO/WHO 1971 
as cited in Thimm 1982; FAO/WHO 1986; Madkour 1989).  None of the Brucella spp. 
have plasmids and all species contain 2 chromosomes with a G + C content between 57-
59%, except for B. suis biovar 3, which has a single combined chromosome (Michaux, 
Paillisson et al. 1993; Corbel 1997; Michaux-Charachon et al. 1997; Jumas-Bilak, 
Michaux-Charachon et al. 1998a; O'Callaghan, Cazevieille et al. 1999; DelVecchio et al. 
2002).   
Brucellae are ubiquitous, and can be found in almost every country and 
environment where there are mammals, from the Mediterranean basin to Japan and North 
America through parts of Mexico, Central and South America to Australia (Thimm 1982; 
Young 1995).  According to Madkour (1989), only 17 countries have been declared 
Brucella-free as of 1989.  Brucellosis is a disease problem in many underdeveloped areas 
such as Africa, China and the Middle East as well as Latin America (Ruben et al. 1991; 
WHO/EMC 1998); however, the incidence of Brucella infection in both man and animal 
has been greatly reduced or eliminated in most developed nations (Corbel 1997).   
In those affected areas, Brucella is of economic importance because it readily 
causes late term abortion, decreased milk production and infertility in infected animals.  
Brucella abortus infection may cause late term abortion and sterility in cattle, (Bang’s 
disease) (Huddleson 1947a; Spink 1956; Cloeckaert, Verger et al. 1996b) while B. suis 
infects swine with resulting abortion in pregnant females and orchitis, epididymitis, and 
sterility in males (Manthei 1948 as cited in Spink 1956; Dalrymple-Champneys 1960). 
Brucella ovis is responsible for abortion and sterility in sheep (Buddle 1956; Cloeckaert 
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et al. 1996b) while B. melitensis is a causative agent of abortion in both goats and sheep 
(Dalrymple-Champneys 1960).   
1.2 Brucella spp. Infection and Dissemination 
Human transmission and Brucella infection may occur by inhalation of infectious 
aerosols, passage across mucous membranes, through a percutaneous route such as cracks 
or cuts in the skin or even through unbroken skin (Kaufmann, Fox et al. 1980; Thimm 
1982; Smith and Ficht 1990; Ruben et al. 1991).  The route of Brucella dissemination 
throughout the body is dependent on dedicated phagocytic cells such as macrophages and 
neutrophils (Mims 1987; Enright 1990).  Once the bacterium is engulfed by a phagocyte 
it resists bactericidal mechanisms and begins to multiply while it is transported through 
the lymphatic system and localized in lymph nodes (Mims 1987; Jawetz et al. 1989).  
Brucellae multiply within lymph nodes causing hemorrhage at 2 to 3 weeks post-
infection and then invade the blood stream leading to eventual bacteremia and 
dissemination throughout the body (Enright 1990; Thoen et al. 1993).   
Studies reveal that in ruminants and humans brucellae localize to the reticulo-
endothelial system, including the liver, spleen, kidneys, mammary glands and bone 
marrow and to nontraditional phagocytic cells such as those of the brain, endocardium, 
bones and joints (Spink 1956; Dalrymple-Champneys 1960; Smith and Ficht 1990).  
Brucellae may colonize both the male and pregnant female reproductive tracts, especially 
the chorionic trophoblasts of the placenta (Smith 1919; Spink 1956; Dalrymple-
Champneys 1960; Meador and Deyoe 1989).     
1.3 Brucella spp. Reproductive Tropism   
In the ruminant, brucellae have a tropism for reproductive organs in both males 
and females locating to the testis, uterus and especially placental tissues (Smith 1919; 
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Meador and Deyoe 1989; Enright 1990; Samartino and Enright 1993).  Placental 
destruction and necrosis resulting in ulcerated chorionic membranes releases large 
numbers of Brucella into the uterine lumen that are transferred to chorionic villi and fetal 
tissues (Anderson, Meador et al. 1986a, b; Enright 1990).  Brucella induced abortion is 
thought to be caused by placentitis followed by vasculitis, decreased placental function 
(Anderson et al. 1986b; Enright 1990), and direct transmission to the fetus (Payne 1959; 
Thoen et al. 1993).  But as noted by Enright (1990), even with severe placentitis, the 
endometrium is left largely untouched.  A combination of factors, in addition to 
decreased placental function, appears to contribute to abortion.  Possibilities include fetal 
stress due to steroid production and the presence of a weak Brucella endotoxin.  Brucella 
infection of both sheep and cows results in increased cortisol production with a 
subsequent decrease in progesterone and increase in estrogen secretion by the placenta 
(Enright 1990).  This sudden change in hormonal levels results in increased endometrial 
PGF2α production leading to premature delivery or possibly abortion (Liggins 1981 as 
cited in Enright 1990; Elzer, Phillips et al. 1996).   
Additionally, the ruminant fetus’ immune system is less able to control Brucella 
infection compared to the adult (Enright 1990).  Large granulomatous lesions, composed 
of macrophages, epithelioid cells, and other polymorphs, form in infected fetal tissues 
such as the lung, kidney, liver and lymphoid tissues.  Fetal infection is characterized by 
elevated cortisol production, presumably due to fetal stress, together with an increase in 
the neutrophil population and a decrease in the number of lymphocytes and eosinophils.  
The presence of a Brucella endotoxin, consisting of lipopolysaccharide (LPS), is also 
thought to contribute to abortion, possibly due to vasculitis and placentomal lesions 
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(Anderson et al. 1986b; Huddelson 1953 and Molello 1963 as reviewed by Samartino and 
Enright 1993).  This notion is plausible since LPS and lipid A from other Gram-negative 
bacteria have abortive properties when present in living microorganisms or administered 
in purified form (Enright 1990).  Presently, however, the process of abortion due to 
Brucella infection and colonization is still not completely understood.   
Why brucellae have a tropism for reproductive organs is still debated.  An initially 
accepted theory held that because brucellae preferentially metabolize the sugar erythritol, 
they locate to areas which contain this carbohydrate, such as the placenta (Pearce 1962 as 
reviewed by Tripathi, Bhatnagar et al. 1977; Samartino and Enright 1993).  Brucella spp. 
share this ability to metabolize erythritol with only one other pathogenic bacterium, 
Serratia marcescens (Slotnick and Dougherty 1972).  Several studies have supported this 
theory, such as those of Tripathi et al. (1977), and Keppie et al. (1965) (as reviewed by 
Tripathi et al. 1977).  Recently Sangari et al. (2000) and DelVecchio et al. (2002) have 
identified the genes responsible for the erythritol catabolic pathway in Brucella.  It was 
proposed that the absence of erythritol in the placentas of humans, rats, mice, rabbits and 
guinea-pigs could explain the rare occurrence of Brucella in the reproductive systems of 
these animals (Keppie 1964 as cited in Samartino and Enright 1993).  However, it has 
been shown that Brucella can infect the placenta of all these species including humans 
(Kniazeff, Elberg et al. 1964; Bosseray 1980; Madkour 1989; Samartino and Enright 
1993).  Additionally, Brucella erythritol catabolizing gene (ery) knockout strains proved 
to be just as virulent as wild type Brucella (Elzer 2002a). Thus, it appears that the ability 
to catabolize erythritol may not be the determining factor that allows Brucella to colonize 
the placenta and cause abortion, but it may confer an advantage.   
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1.4 Brucella Infection and Man 
Brucella is also an important zoonotic pathogen, ranking among the world’s top 
five most common bacterial zoonoses (Sola-Landa, Pizzaro-Cerda et al. 1998).  Members 
of the genus known to infect man include B. melitensis, B. abortus, B. suis and B. canis 
(Spink 1956; Thimm 1982; Ramacciotti 1984; Madkour 1989; Elzer 2002a).  Of the six 
known species of Brucella, B. melitensis is considered the most infectious and virulent to 
man, followed by B. suis and then B. abortus (Table 1) (Spink 1956; Madkour 1989; 
Smith and Ficht 1990).     
Table 1.  Relative Brucella infectious dose for man of the four most virulent species 
(Young 1995; Elzer 2002a). 
   
Virulence to Humans   Species Relative infectious dose 
   
Most Virulent B. melitensis ~1-10 organisms 
   
 B. suis ~1000 
   
 B. abortus >100,000 
   
Least Virulent B. canis ~1,000,000 
   
 
The most common causes of human infection include laboratory acquired infection, 
ingestion of unpasteurized milk, contaminated cheese, and contact with diseased animals, 
especially placental tissues (Dalrymple-Champneys 1960; Young 1975; Fox and 
Kaufmann 1977; Thimm 1982; 1991; Ruben et al. 1991; Corbel 1997; Hong, Tsolis et al. 
2000). 
Brucella infection in man causes a systemic, febrile disease known as brucellosis.  
It has been referred to as undulant fever, Malta fever (B. melitensis), Mediterranean 
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remittent fever, Gibraltar fever, Cyprus fever and neapolitan fever, among others (Spink 
1956; Thimm 1982; Jawetz et al. 1989; Madkour 1989).  Acute, human brucellosis is 
characterized by a cyclic fever, shaking chills, profuse, drenching night and evening 
sweats, weakness, weight loss, nervousness, joint pain, insomnia, headache and 
respiratory trouble in the short term (Spink 1956; FAO/WHO 1986; Jawetz et al. 1989; 
Madkour 1989; DelVecchio et al. 2002).  Other clinical short term signs include 
lymphadenopathy, splenomegaly, hepatomegaly, skin rash, depression and mental 
fatigue, with CNS invasion occurring in < 2% of cases (Spink 1956; Madkour 1989; 
Young 1995). Chronic, long term complications include weakness, sacroiliitis, orchitis, 
epididymo-orchitis, spondylitis, osteomyelitis, bursitis, bone and joint infection, 
dementia, neurological disorders and relapse with recurrent bacteremia (Spink 1956; 
Dalrymple-Champneys 1960; Thimm 1982; FAO/WHO 1986; Jawetz et al. 1989; Young 
1995; Comerci et al. 2001).  Severe cases of brucellosis can demonstrate as bronchitis, 
meningitis and in < 2% of all cases, endocarditis, which is responsible for the majority of 
Brucella-related deaths (Bouza 1987 as cited in Hart, Morgan et al. 1951; Dalrymple-
Champneys 1960; Al-Harthi 1989; Young 1995; Comerci et al. 2001).    
Full recovery from brucellosis is possible with antibiotic therapy.  Rifampicin 
(600-900mg/day) and doxycycline (200mg/day) given for 6 weeks is the most effective 
treatment for eliminating Brucella infection (FAO/WHO 1986).  The incubation period 
between infection and outward clinical signs is thought to average 1-3 weeks, however it 
may be as long as several months (Madkour 1989).  According to an FAO/WHO report 
(1986), natural recovery from brucellosis of average severity takes 1-3 months with 
weakness and fatigue lasting much longer.  As a result of this ability to incapacitate its 
 10
host, some species of Brucella have been investigated as biological warfare agents by 
several governments including the United States (Christopher et al. 1997; Franz et al. 
1997).  Beginning in 1942 and under the direction of the War Reserve Service, several 
potential pathogenic and nonpathogenic biological agents, including Brucella suis, were 
tested as candidates for weaponization (Christopher et al. 1997).  By 1954 B. suis was 
loaded into biological cluster bombs for use by the U.S. Airforce (Franz et al. 1997).   
1.5 Brucella Intracellular Colonization  
1.5.1 Brucella General Intracellular Characteristics 
Members of the genus Brucella do not evade phagocytosis by professional 
phagocytes.  According to Spink (1956), phagocytosis of brucellae by macrophages and 
polymorphonuclear (PMN) cells may be necessary for protection and dissemination of 
the bacterium throughout the host.  Brucellae are non-motile and readily ingested by 
macrophages where they multiply, eventually establishing infection within both 
professional and non-professional phagocytic cells (Smith and Ficht 1990).  Other 
virulent facultative intracellular pathogens with this ability to colonize phagocytic cells 
include Mycobacterium, Legionella, Shigella, Listeria, Salmonella, Yersinia, Nocardia 
and possibly Neisseria (Kiderlen, Kaufmann et al. 1984; Frenchick, Markham et al. 1985; 
Mims 1987; Salyers and Whitt 1994; Russell 2000; Cianciotto 2001).  Exactly how 
brucellae withstand the bactericidal environment of such cells as macrophages and 
neutrophils is not entirely understood; however, there appears to be more than one 
mechanism involved.  Studies conducted by Detilleux, Deyoe et al. (1990a, b, 1991) 
show that brucellae do not induce their own uptake by non-phagocytic cells.  After 
phagocytosis, brucellae are found in coated pits, suggesting they are phagocytized by 
non-professional phagocytes, such as Vero cells, through a receptor-mediated process 
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that has not yet been elucidated.  One particular study has confirmed these observations 
with non-professional phagocytes and provided new evidence that Brucella uptake into 
macrophages is also receptor mediated.  Using transposon mutagenesis, Sola-Landa et al. 
(1998) have uncovered a possible two component sensory and regulatory (BvrR-BvrS) 
system employed by B. abortus, which may be responsible for invasion, intracellular 
survival and replication within Hela cells and macrophages.  The BvrR-BvrS system of 
Brucella is closely related to similar sensory/regulatory systems in Rhizobium meliloti 
(Chvl-ExoS) and Agrobacterium tumefaciens (Chvl-ChvG) (Sola-Landa et al. 1998).  It 
appears that the Brucella BvrR-BvrS system is responsible for outer membrane properties 
that control bacterial susceptibility to polycations and surfactants, host cell penetration 
and invasion, and intracellular survival and phagosomal trafficking (Sola-Landa et al. 
1998).   
1.5.2 Brucella Within Professional Phagocytes 
Within professional phagocytes, such as macrophages, brucellae appear to survive 
and multiply within the phagosome and phago-lysosome, similar to pathogens like 
Leishmania spp. and Coxiella burnetti (Harmon, Adams et al. 1988; Rabinovitch 1996 as 
cited in Sinai and Joiner 1997; Porte, Liautard et al. 1999).  Recent work by Rittig, 
Alvarez-Martinez et al. (2001) suggests that when brucellae (B. suis and B. melitensis) 
are phagocytized by human monocytes, they are sequestered in phagosomes with either 
tightly (TP) or loosely (SP) apposed walls.  Brucellae found in the TP phagosomes 
readily survive acidification whereas brucellae found in SP phagosomes are killed in the 
acidic environment resulting from phagosome-lysosome fusion.  
Once phagosome-lysosome fusion occurs, brucellae appear to be resistant to 
degradation at a pH of 3.2-4.0 and begin multiplying within the acidified compartment 
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(Kulakov, Guigue-Talet et al. 1997; Porte et al. 1999; Arenas, Staskevich et al. 2000; 
Endley, McMurray et al. 2001).  This resistance to lysosomal degradation is also seen in 
other bacteria such as Mycobacterium lepraemurium, which is protected by a 
hydrophobic mycoside capsule, and Salmonella typhimurium (Mims 1987).  Evidence 
suggests that acidification of the Brucella containing phagosome promotes the synthesis 
of bacterial stress proteins including GroEL and DnaK which are essential for replication 
of the bacteria within macrophages (Lin and Ficht 1995; Kohler, Teyssier et al. 1996; 
Rafie-Kolpin, Essenberg et al. 1996; Porte et al. 1999; Arenas et al. 2000; Rittig, 
Alvarez-Martinez et al. 2001; Boschiroli, Ouahrani-Bettache et al. 2002).  Brucellae 
share this unique environment for transcriptional activation with at least four other 
pathogens such as Leishmania, Coxiella, Legionella pneumophila (Sturgill-Koszychi and 
Swanson 2000), and Salmonella typhimurium.  Upon phagosome acidification 
Salmonella activates pag gene expression, which are virulence and survival genes under 
the direction of the phoP/phoQ sensory/regulaory system that are regulated by stressful 
conditions such as carbon limitation and low pH typically found within the phagosome of 
a macrophage (Aranda, Swanson et al. 1992; Salyers and Whitt 1994; Rathman, Sjaastad 
et al. 1996; Joiner 1997; Russell 2000; Cianciotto 2001; Rittig et al. 2001; Boschiroli et 
al. 2002).  
1.5.2.1 Brucellacidal Activity of PMNs and Macrophages 
Virulent strains of Brucella can readily invade and multiply within both 
macrophages and PMN cells (Young 1995).  Macrophages, however, are considered the 
primary phagocytic host (Mims 1987; Madkour 1989).  Why brucellae are rarely found in 
PMN cells such as neutrophils probably has to do with both their increased bactericidal 
activity and limited life span (Madkour 1989; Thoen et al. 1993).  PMN cells are known 
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to produce a larger quantity of antimicrobial oxygen species, thus making them more 
effective than monocytes or macrophages at killing certain fungi and bacteria (Mims 
1987).  In addition, activation may be required for full macrophage antimicrobial activity, 
as evidenced by the parasites Leishmania, Listeria and Toxoplasma gondii, which can 
survive phagocytosis by non-activated macrophages (Mims 1987).  However, compared 
to Listeria, Brucella is more resistant to killing by activated macrophages (FAO/WHO 
1986).  The limited life span of a PMN, usually two to three days in man, compared to 
several weeks or months for macrophages, may also be a limiting factor, not allowing for 
Brucella replication and persistence (Mims 1987; Atlas 1997).  The basic bactericidal 
mechanisms of both macrophages and PMN cells will be discussed in section 1.6. 
1.5.3 Brucella Within Non-Professional Phagocytes 
Within non-professional phagocytes, like Vero cells, Hela cells and trophoblasts, 
Brucella takes a different course altogether, and is not solely located in phagosomes or 
phago-lysosomes.  As with professional phagocytic cells, brucellae may be found within 
phagosomes of non-dedicated phagocytic cells (Detilleux, Deyoe et al. 1990a; Pizzaro-
Cerda, Moreno et al. 1998).  According to Detilleux et al. (1990a), the fate of these 
brucellae after phagosome-lysosome fusion appears to be death and degradation.  An 
important discovery made by Anderson et al. (1986a, b) in two studies revealed that 
within the placenta of goats, B. abortus is endocytosed by erythrophagocytic trophoblasts 
and subsequently localize and multiply within the rough endoplasmic reticulum (RER) of 
chorioallantoic trophoblasts.  This localization of brucellae to cisternae of the RER or ER 
(endoplasmic reticulum)-like structures has also been well established in other non-
phagocytic cells including Vero cells (Detilleux, Deyoe et al. 1990b; Detilleux et al. 
1990a; Detilleux, Deyoe et al. 1991), Hela cells (Pizzaro-Cerda et al. 1998; Delrue, 
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Martinez-Lorenzo et al. 2001), as well as in further experiments using trophoblasts 
(Anderson et al. 1986a, b; Samartino and Enright 1993).  The only other bacterium that 
finds a similar, although not identical, ER-like intracellular niche is Legionella 
pneumophila (Katz and Hashemi 1982; Horwitz 1983).  The purpose for RER 
colonization by Brucella has only been speculative, but possibilities include use of 
trophoblastic RER produced proteins for bacterial metabolism or as glycoprotein 
components of the bacterial membrane (Anderson et al. 1986b).  
1.6 Brucella Intracellular Survival 
1.6.1 Intracellular Environmental Conditions 
Once phagocytized by macrophages or PMN cells, brucellae must endure an 
onslaught of bactericidal elements.  Antimicrobial mechanisms available to phagocytes 
can be separated into those that are oxygen-dependent, non-oxygen dependent or nitrogen 
dependent (Mims 1987; Atlas 1997).  Once phagocytized, brucellae encounter an initial 
oxidative burst which generates reactive oxygen intermediates such as superoxide anions, 
hydrogen peroxide and hydroxyl radicals (Mims 1987).  In addition, PMN cells and 
circulating monocytes catalyze the myeloperoxidase-mediated halogenation of hydrogen 
peroxide, leading to the production of hypohalides (OCL-) and singlet oxygen (Elsbach 
and Weiss 1983; Mims 1987; Baldwin, Jiang et al. 1993; Paul 1993).  These oxygen and 
halogenated radicals damage DNA, proteins and bacterial membrane lipids (Mims 1987; 
Paul 1993).  Nitrogen-dependent antimicrobial activity includes the production of 
reactive nitrogen intermediates like nitrate, nitrite and nitric oxide (Atlas 1997). 
Brucellae must also contend with oxygen independent bactericidal mechanisms 
used by professional phagocytes that result from phagosome-lysosome fusion and 
acidification of the phagosome to a pH of 3.5 (Mims 1987; Porte et al. 1999).  
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Phagocytes release hydrolytic enzymes, such as lysozyme and acid hydrolases, into the 
phagosome as well as antimicrobial agents like defensins and cationic proteins which are 
found in PMN cells and some macrophages (Mims 1987; Paul 1993; Porte et al. 1999).  
Professional phagocytes also use nutritional deprivation against ingested microbes.  PMN 
cells secrete a B12-binding protein, while both macrophages and PMN cells discharge 
lactoferrin into the phago-lysosome, which competes with intracellular bacteria for free 
iron (Mims 1987; Atlas 1997).   
1.6.2 Intracellular Survival Mechanisms  
1.6.2.1 Brucella Manipulation of Phagosomal Maturation 
After phagocytosis, Brucella spp., like Mycobacterium, Legionella, Chlamydia, 
Toxoplasma, Salmonella and Listeria, alter the process of phagosome maturation and 
phagosome acidification (Aranda et al. 1992; Alvarez-Dominguez, Roberts et al. 1997; 
Sinai and Joiner 1997; Arenas et al. 2000).  Upon phagocytosis by macrophages, B. 
abortus may alter phagosomal maturation and intracellular transport in at least half of 
their vacuoles, significantly delaying interaction with lysosomes (Arenas et al. 2000; 
Endley et al. 2001; Rittig et al. 2001).  Recently, Naroeni, Jouy et al. (2001) have shown 
with B. suis that delayed phagosomal maturation may be due to a phagosomal membrane 
modification that prevents or delays lysosomal recognition.  This modification is believed 
to be due to an active process by which brucellae alter the phagosomal membrane since 
killed brucellae do not cause delayed phagosomal maturation.  Frenchick et al. (1985) 
suggest this modification is not associated with the Brucella LPS.  
1.6.2.2 Brucella Inhibition of Phagocyte Degranulation 
Instead of directly challenging the host’s natural bactericidal machinery, brucellae 
may use stealth to establish an intracellular replication niche.  Studies conducted by Riley 
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and Robertson (1984a, b) suggest that virulent, smooth strains of B. abortus fail to 
stimulate human or bovine PMN cell degranulation at levels comparable to extracellular 
parasites such as Staphylococcus epidermidis.  Intracellular degranulation by PMN cells 
normally involves the fusion of microbe-containing phagosomes with lysosomes, 
releasing bactericidal agents such as reactive oxygen species, proteases and defensins 
(Riley and Robertson 1984b, a).  Furthermore, the level of degranulation caused by 
glutaraldehyde-killed B. abortus was comparable to viable B. abortus, suggesting that a 
surface molecule of Brucella either allows the bacteria to enter the macrophage 
undetected or inhibits normal degranulation by some unknown mechanism (Riley and 
Robertson 1984b, a).  Other researchers have obtained similar results showing inhibited 
degranulation while also using bovine PMN cells (Canning, Roth et al. 1986).    
A major departure from the theory of a surface macromolecule as the inhibitor of 
degranulation is the identification of two molecules, produced by live B. abortus, which 
alone suppress PMN cell degranulation (Canning, Roth et al. 1985; Canning et al. 1986).  
Adenine and 5’-guanosine monophosphate (GMP) were found to inhibit up to 80% and 
65% respectively, of the release of peroxidase-positive granules from bovine PMN cells 
(Canning et al. 1986).  Similar results have been obtained in experiments with another 
pathogen, Haemophilus somnus (Chiang, Kaeberle et al. 1986), where the secretion of 
GMP and adenine also inhibit PMN function (Canning et al. 1986).    
1.6.2.3 Brucella Inhibition of Macrophage Activation 
Macrophage activation is essential for immune control of microbial infections 
(Mims 1987).  Activated macrophages have increased lysosomal enzyme content and 
bactericidal mechanisms, which are necessary for controlling intracellular pathogens 
(Cossart, Boquet et al. 2000).  Thus, activated as opposed to non-activated macrophages 
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have an enhanced ability to resist infection and/or manage Brucella, mycobacteria, 
Listeria monocytogenes, protozoans such as Toxoplasma gondii and Leishmania, as well 
as some viral agents (Pomales-Lebron and Stinebring 1957; Fitzgeorge, Solotorovsky et 
al. 1967; Ralston and Elberg 1968; Mims 1987; Unane 2000).  Activation may occur 
through a T-cell dependent or independent manner.  The T-cell independent pathway 
relies on a cytokine cascade that begins when the macrophage encounters a pathogen, 
triggering the release of interleukin-12 (IL-12) and tumor necrosis factor-α (TNF-α).  IL-
12 and/or TNF-α stimulate natural killer (NK) cells to secrete interferon gamma (IFN-γ) 
that, in turn, activates other macrophages (Paul 1993; Unane 2000).  The T-cell 
dependent pathway involves the digestion and presentation of bacterial proteins on the 
surface of macrophages and other antigen presenting cells (APCs), which are attached to 
major histocompatibility complexes (MHCs).  Bacterial antigens bound to these MHC 
class II molecules, in the presence of IL-12, stimulate CD4+ cell differentiation into Th1 
(T-helper) cells that subsequently release IFN-γ which activates macrophages (Salyers 
and Whitt 1994; Unane 2000).  
1.6.2.4 Brucella Inhibition of Phagocyte Cytokine Signaling 
The importance of both IFN-γ and TNF-α to macrophage activation and the 
control of Brucella infection have been shown in numerous studies (Jones and Winter 
1992; Stevens, G. W. Pugh et al. 1992; Baldwin et al. 1993; Jiang and Baldwin 1993; 
Jiang, Leonard et al. 1993; Baldwin and Winter 1994; Caron, Peyrard et al. 1994; 
Murphy, Parent et al. 2001).  Moreover, Brucella survival within human macrophage-
derived cells appears to be at least partially dependent on it’s ability to inhibit the 
secretion of TNF-α and thus avoid macrophage activation via IFN-γ (Caron et al. 1994; 
Caron, Gross et al. 1996).  Precedent for this virulence factor is found in other pathogens 
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such as Yersinia pestis, Listeria monocytogenes, Bacillus anthracis, and Mycobacterium 
avium all of which inhibit TNF-α production by their hosts (Furney, Skinner et al. 1992; 
Ugalde 1999).  Interestingly, Rhodopseudomonas sphaeroides, a purple, nonsulfur 
bacteria found in α-Proteobacteria produces a lipid A that also inhibits TNF- α 
production by macrophages (Takayama, Qureshi et al. 1989; Madigan et al. 2000).  
Studies by Caron et al. (1994, 1996) found that B. suis infected human-derived 
macrophages could not accumulate TNF-α mRNA, and that Brucella LPS was not 
responsible.  They also concluded that inhibition of TNF-α production was the result of 
an active process by the bacterium since chloramphenicol treated and killed B. suis did 
not trigger human macrophages to secrete TNF-α.  Furthermore, Caron et al. (1996) have 
tentatively identified the Brucella inhibitor of TNF-α as a protein, based on its protease 
and heat sensitivity, of 45 to 50 kDa.   
Research by Zhan, Liu et al. (1996) has reevaluated the centrality of TNF-α to 
macrophage activation and brucellacidal activity.  Using a mouse model, they determined 
that the most important cytokine for macrophage activation is not TNF-α, but rather IL-
12.  Zhan et al. (1996) assert that although both TNF-α and IFN-γ are necessary for 
complete control of Brucella infection, TNF-α contributes to brucellacidal activity by an 
IFN-γ independent pathway, whereas IL-12 is mainly responsible for the activation of 
NK cells and secretion of IFN-γ leading to macrophage activation.  This view is 
supported by work from Zhou, Miller et al. (1998), who also suggest TNF-α induced 
macrophage activation is independent of IFN-γ.  Additionally, recent work proposes that 
monocyte programmed cell death is inhibited by brucellae through a TNF-α and LPS-
independent mechanism (Gross, Terraza et al. 2000).  Specifically, Gross et al. (2000) 
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assert that the apoptotic affect of IFN-γ towards human phagocytic monocytes is blocked 
after B. suis infection.  An opposing view, however, is held by Zhan and Cheers (1998) 
and Flesch et al. (1995) (as reviewed by Zhan and Cheers 1998) who advocate a direct 
relationship among TNF- α, IL-12 and IFN- γ.   
1.6.2.5 Brucella Outer Membrane  
The Brucella outer membrane has no pili, fimbriae or capsular components, but 
simply contains phospholipids, outer membrane proteins (Omp), and LPS, of which only 
the O-polysaccharide component of the LPS is considered a true virulence factor (Smith 
and Ficht 1990; Cloeckaert, Verger et al. 1996a; Elzer 2002a).  Brucellae also have a high 
content of ornithine lipids (17-32% of total lipid) in their outer membrane (Martin and 
Hancock 1990).  Ornithine lipids are neutral lipids made up of ornithine, ethylene glycol 
and fatty acids, they resist hydrolysis by phosopholipases and possibly serve as a 
stabilizing agent for Brucella conveying resistance to EDTA and polycations by shielding 
negatively charged groups in the LPS (Cherwonogrodsky, Dubray et al. 1990; Moreno 
and Moriyon 2002).   
1.6.2.5.1 Brucella LPS 
The lipopolysaccharide of Brucella contains the main components of extracellular 
toxicity, lipid A, and one of the major Brucella antigens, the O-polysaccharide.  The 
presence or absence of the O-polysaccharide/antigen in the LPS layer is the molecular 
basis of Brucella smooth and non-smooth (mucoid or rough) morphology (Caroff, Bundle 
et al. 1984; FAO/WHO 1986; Perry and Bundle 1990; Smith and Ficht 1990; Corbel 
1997; Ugalde, Czibener et al. 2000).  The Brucella smooth phenotype is naturally more 
virulent, while non-smooth brucellae are normally avirulent (Riley and Robertson 1984b, 
a; Young, Borchert et al. 1985; FAO/WHO 1986; Harmon et al. 1988; Smith and Ficht 
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1990; Roop II 1991; Rasool, Freer et al. 1992; Thoen et al. 1993; Baldwin and Winter 
1994; Kulakov et al. 1997).  According to Riley and Robertson (1984a), B. abortus 
smooth and non-smooth strains elicit similar amounts of degranulation from bovine and 
human PMN cells, however, the smooth strains, unlike the non-smooth versions, are 
resistant to the phagocyte’s microbicidal action.  The difference in intracellular success 
between non-smooth and smooth strains suggests that intracellular survival is dependent 
on cell surface components (see previous references).  But exceptions to this rule do 
exist, as seen with B. canis and B. ovis, which are naturally occurring, virulent non-
smooth strains, and B. neotomae, which is an avirulent smooth strain (FAO/WHO 1986; 
Smith and Ficht 1990; Baldwin and Winter 1994; Sangari and Aguero 1996; Kulakov et 
al. 1997).  The mehods by which smooth and non-smooth strains of Brucella differ in 
their protection from intracellular bactericidal mechanisms appear to be complex, and not 
solely dependent on bacterial surface structure.  Evidence to this point is given by 
Kulakov et al. (1997), who found that B. suis and B. melitensis non-smooth mutants are 
able to withstand acidic pH as efficiently as non-mutated smooth strains.  
 The O-polysaccharide/antigen in smooth strains of Brucella may be found in 
either an A or M epitope, both of which can be expressed on the same organism, but in 
different quantities.  The A epitope, examined from B. abortus, is a linear molecule 
composed of 96-100 residues of α-1, 2-linked 4,6-dideoxy-4-formamido-D-
mannopyranose, also known as D-Rhap4 NFo (Cherwonogrodsky et al. 1990; Perry and 
Bundle 1990).  The M epitope from B. melitensis is identical to the A epitope except that 
it is a series of repeating pentasaccharide units containing one α-1,3-linked and four α-
1,2-linked monosaccharide residues (FAO/WHO 1986; Bundle, Cherwonogrodzky et al. 
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1989).  Brucellae of the smooth type that mutate and lose this O-polysaccharide chain 
exhibit the non-smooth phenotype (Sola-Landa et al. 1998).  Unlike other Gram-negative, 
enterobacterial LPS endotoxins, Brucella LPS is non-pyrogenic and much less toxic to its 
host, especially in the non-smooth (rough) form (Moreno, Berman et al. 1981; 
Cherwonogrodsky et al. 1990; Rasool et al. 1992).  In a study using human neutrophils, 
Rasool et al. (1992) found that 100 times more Brucella LPS and 1000 times more lipid 
A were required to elicit an equivalent lysosome release from phagocytes compared to 
LPS from Salmonella typhimurium.  In addition, Brucella LPS and lipid A were several 
orders of magnitude less toxic than Salmonella LPS.  Rasool et al. (1992) speculated that 
the low biological toxicity of Brucella LPS might be a factor allowing the intracellular 
survival and persistence of brucellae inside phagocytes. 
1.6.2.5.2 Brucella Outer Membrane Proteins (Omp)  
 Brucella spp. possess three classes of outer membrane proteins (Omp).  The first 
class, group 1, contains two Omps of 88 and 94 kDa; group 2 includes proteins of 35-43 
kDa, and is composed of two Omps, 2a (41 kDa) and 2b (43 kDa); group 3 incorporates 
proteins of 16.5-34 kDa and contains Omp25 (25 kDa), and Omp31 (31 kDa) (Verstreate, 
Creasy et al. 1982; Douglas, Rosenberg et al. 1984; Mayfield, Bricker et al. 1988; 
Cherwonogrodsky et al. 1990; Bowden, Cloeckaert et al. 1995; Cloeckaert, Jacques et al. 
1995; Cloeckaert et al. 1996a; Lindler, Hadfield et al. 1996; Vizcino, Cloeckaert et al. 
1996; Edmonds, Cloeckaert et al. 2001; DelVecchio et al. 2002).  The group 1 Omps are 
believed to be minor components of the cell envelope, while group 2 Omps are assigned 
porin structural properties (Douglas et al. 1984; FAO/WHO 1986; Smith and Ficht 1990).  
Membrane proteins in group 3 are structural in nature; Omp31 is complexed to the 
peptidoglycan whereas Omp25, which is highly conserved among all six Brucella 
 22
species, is bound to the peptidoglycan and LPS (Madkour 1989).  It should be noted that 
while some Omps are considered major membrane components in one species, they may 
only be a minor membrane constituent of another species, i.e., Omp 31 is a major protein 
in B. melitensis but is absent in B. abortus (Vizcino et al. 1996). Research has confirmed 
that every group of Brucella outer membrane protein elicits an antigenic response from 
the host (Dubray and Bezard 1980; Mayfield et al. 1988; Limet, Cloeckaert et al. 1993, 
1995, 1996a; Bowden et al. 1995; Lindler et al. 1996; Vizcino et al. 1996; Bowden, 
Cloeckaert et al. 1998).  Research by Edmonds et al. (2001) has confirmed the 
importance of Omps to Brucella intracellular survival.  They demonstrated that B. 
abortus Omp25 mutants exhibited lower levels of survival in bovine macrophages and 
trophoblasts compared to wild type strains.   
1.6.3 Other Brucella Virulence Genes and Gene Products 
 Although brucellae exhibit many of the same characteristics as other intracellular 
pathogens, i.e., survival and multiplication within the phagosome and inhibition of cell 
signaling, the majority of genes involved in Brucella-related virulence have not been 
discovered (Smith and Ficht 1990; Robertson, Kovach et al. 2000).  One large step 
towards identifying and confirming the presence of virulence factors and other essential 
genes comes from a sequence analysis of the entire B. melitensis 16M genome by 
DelVecchio et al. (2002).  
 Although their true importance to Brucella pathogenicity has not yet been 
established, the genes, proteins and pathways listed in Table 2 likely play a role in 
virulence.  In common with most other bacterial species, brucellae also employ a number 
of specialized enzymes, which are not necessarily thought of as virulence factors, for 
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Table 2.  Putative virulence-related genes, proteins or pathways in B. melitensis 16M. 
 
Protein, Gene or 
Pathway Identified in B. 
melitensis 
Homologous to: Reference 
Hemolysin, α-hemolysin, 
hemolysin III 
 DelVecchio et al. 2002 
Adhesin protein precursors AidA-I Sanchez, Zandomeni et al. 2001; 
DelVecchio et al. 2002 
Invasin precursor InvA of Mesorhizobium 
loti and Burkholderia 
cepaca 
DelVecchio et al. 2002 
acvB VirJ of Agrobacterium 
tumefaciens 
DelVecchio et al. 2002 
mviN Virulence protein of 
Salmonella 
DelVecchio et al. 2002 
Lipid IV synthesis  DelVecchio et al. 2002 
UDP-N-acetlymuramoyl 
pentapeptide synthesis 
 DelVecchio et al. 2002 
Ortholog of cydB cydB of B. abortus Endley et al. 2001; DelVecchio et al. 
2002 
Symbiosis protein Protein E of 
Bradyrhizobium 
japonicum 
DelVecchio et al. 2002 
entD  DelVecchio et al. 2002 
Adaptive acid tolerance 
regulatory protein 
ActR of 
Bradyrhizobium 
DelVecchio et al. 2002 
 
protection and repair in harsh intracellular conditions.  Brucella melitensis encodes DNA 
repair proteins and ion, amino acid, carbohydrate, nutrient and metal transporters, with 
the exception of a ferrous iron transporter (DelVecchio et al. 2002).  Protein expression 
during stressful conditions has been well characterized in Brucella spp. (Lin and Ficht 
1995; Phillips, Elzer et al. 1995; Kohler et al. 1996; Rafie-Kolpin et al. 1996; Kim and 
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Mayfield 2000; Robertson et al. 2000; Teixeira-Gomes, Cloeckaert et al. 2000).  Phillips 
et al. (1995) and Elzer et al. (1996) have shown that mutation of the htrA gene results in 
decreased resistance of B. melitensis and B. abortus to oxidative damage and phagocyte 
killing.   
In addition to the identification of coding regions for cold and heat shock proteins 
in B. melitensis (DelVecchio et al. 2002), several studies have revealed increased 
production of the molecular chaperones DnaK and GroEL by B. abortus and B. melitensis 
under conditions of macrophage phagocytosis, acid and heat stress (Rafie-Kolpin et al. 
1996; Teixeira-Gomes et al. 2000).  To complement this, Kohler et al. (1996) have shown 
decreased B. suis survival under conditions of macrophage phagocytosis and acid stress 
when dnaK is mutated.  Robertson et al. (2000) studied the activity and function of the 
stress response protease Lon in B. abortus and found it may play a critical role in 
turnover of heat-damaged proteins in the initial stages of infection and colonization.  
With the exception of B. neotomae and B. suis biovar 2, all brucellae encounter and 
scavenge highly reactive oxygen species within the phagosome primarily with a catalase 
and two types of superoxide dismutases (SOD), a Fe-Mn SOD and a Cu-Zn SOD 
(Bricker, Tabatabai et al. 1990; Sriranganathan, Boyle et al. 1991; Tatum, Detilleux et al. 
1992; Rafie-Kolpin et al. 1996; Kim and Mayfield 2000; Teixeira-Gomes et al. 2000; 
DelVecchio et al. 2002).  Disabling B. abortus catalase expression through mutation of 
the catalase promoter, oxyR, causes increased sensitivity of B. abortus to hydrogen 
peroxide (Kim and Mayfield 2000).  Moreover, virulence and level of catalase expression 
appear to be positively correlated (Huddleson and Stahl 1943).  And after mutation of the 
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Cu-Zn SOD, Tatum et al. (1992) found that BALB/c mice were better able to control the 
growth and progression of B. abortus during early stages of infection.   
1.7 Limitations of the Murine and Bovine Models of Brucellosis 
The ability of brucellae to survive within phagocytic cells is also a function of the 
mammalian host infected, i.e., mouse, human or cow.  A large difference exists between 
mouse and human macrophage susceptibility to Brucella infection and persistence 
(Cheers and Pagram 1979; Caron et al. 1996; Gross et al. 2000).  As supported by several 
studies (Zhan and Kelso 1993; Caron et al. 1994, 1996; Zhan and Cheers 1995, 1998; 
Liautard, Gross et al. 1996), murine macrophages readily produce TNF-α upon infection 
with live Brucella whereas human cell lines do not.  It has been postulated that the 
secreted TNF-α inhibitory factor is species specific, and mouse cell lines are resistant to 
inhibition (Caron et al. 1996; Liautard et al. 1996).  This may help to explain some 
contradictory results regarding TNF-α production and/or inhibition seen in the literature.  
In addition, while Brucella avoids the bactericidal activity of IFN-γ-induced human 
monocytes, it is regularly cleared in mouse macrophages induced in the same manner 
(Stevens et al. 1992; Zhan and Cheers 1995; Gross, Spiesser et al. 1998; Gross et al. 
2000).    
Bovine phagocytes also are markedly different from their human counterparts.  In 
studies conducted with B. abortus smooth strain 45/0, Riley and Robertson (1984a) found 
that human PMN cells were not as effective in killing phagocytized brucellae when 
compared to bovine PMN cells.  The difference in brucellacidal activity appeared to be 
due to more extensive degranulation in bovine as compared to human PMN cells (Riley 
and Robertson 1984b, a).  This decreased ability to control a Brucella infection may help 
explain the recurring nature of untreated human brucellosis. 
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1.8 Brucella Type IV Secretion and Virulence - The vir Family 
1.8.1 vir General Characteristics 
 In contrast to typical type I, II, III and V secretion systems which only export 
proteins, Gram-negative bacterial type IV secretion systems are believed to be specialized 
for the secretion of nucleoprotein complexes in addition to straight protein products such 
as multisubunit bacterial toxins (Christie and Covacci 2000).  As proposed by Christie 
and Covacci (2000), the type IV secretion family is thought to have originated from a 
system originally designed for conjugative transfer of DNA between bacterial cells.  
Through horizontal transfer and association with other types of genes, different classes of 
bacteria may have adapted the type IV secretion machinery to their environments, or 
exploited new niches.  Specifically, the type IV secretion system is used for the exchange 
of protein-DNA complexes between bacteria, as seen in Escherichia F plasmid transport, 
between bacteria and eukaryotic cells, as with Agrobacterium T-complex transfer to plant 
root cells, and for extracellular secretion of polypeptide toxins, as in Bordetella toxin 
export (Christie and Covacci 2000; Sieira et al. 2000).   
 Brucellae do not contain typical, complete operons for type I, II or III secretion, 
however, they do encode components for sec-dependent, sec-independent, flagellar-
specific type secretion systems, and type IV and V secretion systems (DelVecchio et al. 
2002; Moreno and Moriyon 2002).  The Brucella type IV secretion system is similar to 
secretion systems in other symbionts and pathogens within α-Proteobacteriacae (Christie 
and Covacci 2000; DelVecchio et al. 2002).  Type IV secretion in all Brucella species, 
including B. melitensis, is encoded by virB located on chromosome II (O'Callaghan et al. 
1999; DelVecchio et al. 2002).  Brucella virB genes are sequentially related to genes in 
type IV secretion systems found in other closely related bacteria; e.g., the vir system of 
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Agrobacterium tumefaciens, ptl transporter of Bordetella pertussis (Weiss, Johnson et al. 
1993), cag pathogenicity island of Helicobacter pylori (Covacci, Telford et al. 1999), 
dot/icm of Legionella pneumophila , virB of Rickettsia prowazekii (Christie and Covacci 
2000), tra of Escherichia coli (Pohlman, Genetti et al. 1994; Christie 1997; Sieira et al. 
2000), magB of Actinobacillus actinomycetemcomitans (Galli, Chen et al. 2001; Novak, 
Dougherty et al. 2001), an unnamed type IV system in Rickettsia prowazekii and 
exporters in Mesorhizobium, Yersinia and Xylella, (O'Callaghan et al. 1999; Ugalde 
1999; Christie and Covacci 2000; Sieira et al. 2000; DelVecchio et al. 2002).   
    The virB regions of B. suis and B. melitensis are composed of 12 linearly 
arranged open reading frames (ORF), whereas B. abortus contains an additional 13th ORF 
that precedes and overlaps ORF12 (O'Callaghan et al. 1999; Sieira et al. 2000; 
DelVecchio et al. 2002).  There exist 2 palindromic, repeat sequences (BruRS1 and 
BruRS2) in the virB region, the first is between virB1 and virB2, while the second is after 
virB12 (Halling and Bricker 1994; O'Callaghan et al. 1999; Sieira et al. 2000; Boschiroli 
et al. 2002).  Two researchers have proven that despite this first palindrome, Brucella 
virB genes are transcribed as an operon starting from virB1 (Sieira et al. 2000; Boschiroli 
et al. 2002).  However, some disagreement exists between these two studies as to whether 
the virB operon is turned on during early stationary or early exponential phase.  A 
possible explanation for this discrepancy may be that the previous studies employed 
different species of Brucella, namely B. abortus (Sieira et al. 2000) and B. suis 
(Boschiroli et al. 2002).  Using B. suis, Boschiroli et al. (2002) were the first to show virB 
operon induction in response to environmental stress.  By mimicking the macrophage 
intracellular environment, they demonstrated that acid stress, elevated temperature (37oC) 
 28
and nutritional deprivation were all positive regulators of virB expression.  Additionally, 
translation of each virB gene is thought to occur independently since possible ribosome 
binding sites are found upstream of all B. suis virB genes (O'Callaghan et al. 1999). 
Very little is known about the actual structure encoded by the Brucella virB 
operon.  However, between genera, the Brucella virB operon is closely related to the tra 
system of the broad-host-range plasmid pKM101 found in E. coli and to the virB genes of 
Agrobacterium tumefaciens, from which it’s name was taken (Stachel and Nester 1986; 
Lessl, Balzer et al. 1992; O'Callaghan et al. 1999; Christie and Covacci 2000; Sieira et al. 
2000; DelVecchio et al. 2002; Moreno and Moriyon 2002).  O’Callaghan et al. (1999) 
have revealed that at the protein level, the B. suis virB operon is more closely related to 
the ptl operon of Bordetella pertussis than to virB of Agrobacterium or the tra system of 
E.coli.  But since 11 genes of the Brucella melitensis virB share sequence and 
organizational similarity with the virB operon of Agrobacterium, structural and functional 
characteristics of the Brucella system can be speculated (O'Callaghan et al. 1999; 
DelVecchio et al. 2002).  Like the Agrobacterium type IV system, the Brucella virB 
probably codes for proteins that form a gated, pilus-like structure that spans the inner and 
outer bacterial membranes as well as the eukaryotic cell membrane (Ward, Akiyoshi et 
al. 1988; Kuldau, Vos et al. 1990; Christie and Covacci 2000).  While the Agrobacterium 
pilus penetrates the eukaryotic plant cell envelope from the outside, it is reasonable to 
suspect the Brucella pilus would gain access to the mammalian host cell cytoplasm by 
spanning the phagosome where it has been localized (Christie and Covacci 2000; Rittig et 
al. 2001).   
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Using functional studies of the Agrobacterium virB encoded proteins as a guide, 
Brucella virB protein characteristics have been predicted (Table 3).  The exact function 
Table 3.  Predicted function of Brucella virB operon components (adapted from 
O'Callaghan et al. 1999; Christie and Covacci 2000; DelVecchio et al. 2002). 
 
virB Gene Product Proposed function 
VirB1 Trans-glycosylase 
VirB2 Pilus formation 
VirB3 Inner membrane protein 
VirB4 Cytoplasmic protein, ATPase 
VirB5 Pilus component 
VirB6 Inner member protein 
VirB7 Lipoprotein, forms complex with VirB9 
VirB8 Inner membrane protein 
VirB9 Periplasmic protein, forms complex with VirB7 
VirB10 Periplasmic protein 
VirB11 Inner membrane protein, ATPase 
VirB12 Function unknown (no homology to other type IV proteins)
 
of the virB encoded secretion system in Brucella is unknown, although knockout studies 
have shown the virB operon is essential for Brucella intracellular survival.  Construction 
of polar mutants of the entire virB operon or non-polar mutants of single virB genes, i.e., 
virB1, 2, 4, 5, 8, 9, 10 and 12, have resulted in an attenuated phenotype in every case and 
almost complete elimination of brucellae from HeLa cells, human monocyte-like cell 
lines and BALB/c mice in some instances (O'Callaghan et al. 1999; Ugalde 1999; 
Foulongne, Bourg et al. 2000; Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001; 
Delrue et al. 2001; Boschiroli et al. 2002).  Comerci et al. (2001) and Delrue et al. (2001) 
have shown that a functional virB operon in B. abortus and B. melitensis is necessary for 
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manipulation of phagosomal trafficking, including delay or prevention of phagosome-
lysosome fusion and establishment of a replication niche.  VirB is not thought to play a 
role in B. abortus entry into the host cell since no reduction in adherence or 
internalization has been observed with any virB mutation (Sieira et al. 2000; Comerci et 
al. 2001).   
The Brucella type IV secretion system is thought to be responsible for the export 
of a virulence factor, as yet unknown, which mediates intracellular survival and 
multiplication (O'Callaghan et al. 1999; Sieira et al. 2000; Comerci et al. 2001).  
Materials exported by bacteria with homologous type IV secretion systems include:   
interleukin-8-inducing factor by Helicobacter pylori, the T-complex by Agrobacterium 
tumefaciens, pertussis toxin by Bordetella and plasmid DNA by Escherichia (Christie 
and Covacci 2000).  Yet, unlike Escherichia and Agrobacterium, brucellae do not contain 
plasmids, and exchange of naturally occurring genetic material has never been observed 
(O'Callaghan et al. 1999).   
Recently, three Brucella products have been identified which are potential 
candidates for virB-mediated export.  The first two are non-protein products of B. abortus 
identified by Canning et al. (1985, 1986) mentioned previously as GMP and adenine, 
which act as inhibitors of the PMN myeloperoxidase (MPO)-H2O2 halide antibacterial 
system.  The second possibility, identified by Caron et al. (1996), is a protein, based on 
its protease and heat sensitivities, of approximately 45 to 50 kDa released by B. abortus 
that inhibits TNF-α production in a human, macrophage-like, neoplastic cell line, U937.  
Either one or both of these inhibitory products may be exported by the virB system of 
Brucella.  However, it should be noted that O’Callaghan et al. (1999) also found a 
 31
Brucella protein inhibitor of TNF-α release, but they acknowledged that virB mutants 
were still able to inhibit TNF-α production. 
1.8.2 virB1 and Virulence 
This body of work demonstrates the inactivation of the first virB gene transcribed 
in the virB operon, virB1.  Efficient knockout of this gene was established by assessing 
the survival and virulence of virB1 mutated strains of B. abortus 2308 and B. melitensis 
16M in macrophage and in-vivo murine models.  Little is known about the Brucella 
virB1 gene and gene product, except what has been predicted by nucleotide and protein 
sequence analysis and comparison to virB1 of Agrobacterium (Christie 1997; 
O'Callaghan et al. 1999).  The virB1 genes of B. melitensis and B. abortus are located on 
chromosome II, are 717 nucleotides long with a GC content of 57 % (DelVecchio et al. 
2002).  By homology to VirB1 of A. tumefaciens and TraL of E.coli, the Brucella VirB1 
is suspected of being a trans-glycosylase, playing a role in the formation of a pore for 
extrusion of macromolecular complexes from the bacterial cell (O'Callaghan et al. 1999; 
Christie and Covacci 2000; Sieira et al. 2000; DelVecchio et al. 2002).  However, 
whether VirB1’s role is essential to virB mediated export is under suspicion after a study 
by Berger and Christie (1994) proposed that VirB1 of A. tumefaciens is supportive but 
not essential for virulence (Christie and Covacci 2000).   
1.9 Brucella Genetic Manipulation 
Members of the genus Brucella are not naturally competent, however, they will 
take up plasmid DNA after chemical treatment or electroporation (Lai, Schurig et al. 
1990; Halling, Detilleux et al. 1991; Elzer, Kovach et al. 1995).  In addition, brucellae do 
not contain any naturally occurring plasmids (Rigby and Fraser 1989; Smith and Ficht 
1990), yet, conjugative transfer of artificially introduced broad-host-range plasmids 
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between brucellae, from E. coli into brucellae and from brucellae into E. coli has been 
demonstrated (Rigby and Fraser 1989; Verger, Grayson et al. 1993).  Genetic 
complementation of all Brucella species is possible using the broad-host-range plasmid 
pBBR1MCS and its derivatives (Kovach, Phillips et al. 1994; Elzer et al. 1995), which is 
not integrated into the genome but stably maintained within all Brucella spp. at low copy 
number (Elzer et al. 1995).  Also, gene replacement by homologous recombination in 
Brucella has been well established as an important method for the creation of specific in-
vivo gene mutations (Lai et al. 1990; Halling et al. 1991; Tatum et al. 1992; Elzer, 
Phillips et al. 1994; Drazek, Houng et al. 1995; Elzer et al. 1995; Phillips et al. 1995; 
Sola-Landa et al. 1998; Kohler, Ouahrani-Bettache et al. 1999; O'Callaghan et al. 1999; 
Sieira et al. 2000; Ugalde et al. 2000; Alvarez-Martinez, Machold et al. 2001; Boschiroli 
et al. 2002).   
One particular technique employed in the process of Brucella gene replacement is 
gene disruption via deletion or insertion mutagenesis, a gene knockout.  This process 
involves cloning the gene of interest into the appropriate plasmid vector, followed by in-
vitro mutation of the gene (Fig. 2).  The mutation may be accomplished by the deletion of 
a portion of the gene or insertion of a positive selectable marker, i.e., antibiotic resistance 
gene (Halling et al. 1991; Madigan et al. 2000), at a particular restriction site within the 
gene.  Once the mutation in the gene of interest is confirmed, the mutagenized plasmid is 
introduced into Brucella where it undergoes a double crossover event, replacing the wild-
type gene with the mutagenized one via homologous recombination.  Both gene deletion 
and insertion result in a loss of gene function. 
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Fig. 2.  Gene disruption by homologous recombination between the wild type (virB1) and 
the mutant gene (virB1::kan).  The wild type gene was cloned into a suitable suicide 
vector, which is not stably maintained in Brucella, and mutagenized by insertion of a 
positive selectable marker (             ).  Transformation of the suicide vector into 
Brucella results in recombination between the homologous regions of the mutated 
and wild type genes leading to gene replacement, in-vivo loss of function and 
expression of the selectable marker.     
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As demonstrated by Halling et al. (1991), narrow host range ColE1-derived 
plasmids (i.e., pBA31-R7) are incapable of replication in Brucella spp. and become 
suicide vectors when they contain Brucella DNA.  In some instances, homologous 
recombination occurs between the vector and the Brucella genome enabling gene 
replacement studies.  One important note regarding ColE1-derived plasmid nomenclature 
is the common practice of referring to ColE1-based plasmids as pMB1-derived, and vice 
versa.  The exact basis for this confusion is unknown, however, it is likely that since both 
types of E. coli based plasmids share many of the same properties, i.e., colicin production 
and immunity, mobilization via the F-factor, mode of replication and same 
incompatibility group, they are considered similar enough to be used interchangeably 
(Bolivar 1979; Bhagwat and Person 1981; Sambrook, Fritsch et al. 1989).  In line with 
this uncertainty, many studies have successfully employed pMB1-based suicide vectors 
in Brucella gene replacement studies, i.e., pGP704, pUC18, pBluescript II, pUC19 and 
pUC4k (Sola-Landa et al. 1998; Kohler et al. 1999; O'Callaghan et al. 1999; Ugalde et al. 
2000; Alvarez-Martinez et al. 2001).  In addition, at least two such gene replacement 
studies have found that the cloning vector pGEM-T, created by Promega Corp. (Madison, 
WI), also functions as an efficient suicide vector in brucellae (Sieira et al. 2000; 
Boschiroli et al. 2002).  PGEM-T is a pMB1-based cloning vector with a mutation in the 
origin of replication RNAI binding region, thereby making it neither like pMB1 nor 
ColE1 (Promega Corp., personal communication).  Research in the present work employs 
pGEM-T as a Brucella gene-cloning vector and suicide plasmid for in-vivo gene 
replacement.   
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Another technique that has been widely used for Brucella gene disruption is in-
vivo transposon mutagenesis, mainly employing a Tn5-based transposon (Smith and 
Heffron 1987; O'Callaghan et al. 1999; Foulongne et al. 2000; Hong et al. 2000; Lestrate, 
Delrue et al. 2000; Endley et al. 2001).  This type of mutagenesis, although not directed 
at a specific locus, has been employed in the discovery of Brucella genes responsible for 
virulence and pathogenesis.  However, because the B. melitensis 16M genome has been 
sequenced and potential virulence factors identified, a targeted, systematic approach to 
gene knockout may now be more productive.   
1.10 Transposition 
  Transposition is the process by which a piece of DNA, a transposable element, is 
translocated from one site to another by an enzyme known as a transposase (Madigan et 
al. 2000).  Three types of transposons are currently known to exist: insertion sequences 
(IS), composite transposons (Tn), and certain types of viruses such as Mu (Bennet 1991; 
Maloy, Cronan et al. 1994; Atlas 1997).  Transposition, as described above, involves the 
use of a transposon, which is a gene or set of genes that code for structural proteins, 
usually 2000-20000 base pairs long, flanked by short inverted terminal repeats, as seen in 
ISs (Atlas 1997; Madigan et al. 2000).  Examples include the transposons Tn5 and Tn7, 
which confer resistance to kanamycin and neomycin, and Tn9, which contains a 
chloramphenicol resistance gene (Smith and Heffron 1987; Atlas 1997; Madigan et al. 
2000).  Transposition of a transposable element can occur by either a conservative or 
replicative manner.  As it’s name implies, replicative transposition is the translocation of 
a copy of a transposable element to a new location, resulting in two copies of the element, 
one at the original site and one at the new site.  Conservative transposition, however, 
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involves the excision of the transposable element from its original location and 
reinsertion at a new site (Madigan et al. 2000).   
Minimally, transposition requires the presence of inverted or direct repeats that 
flank transposable elements, and the transposase, which recognizes and cleaves the 
flanking sequences and then ligates the transposable element at it’s new location.  At 
least two models exist which explain the conservative mechanism of transposition.  In the 
first model, proposed by Arthur and Sherratt, and Shapiro, transposase makes single 
stranded cuts in both the donor and recipient DNA (as reviewed by Bennet 1991).  A 
transposition cointegrate is then formed, known as a “Shapiro intermediate,” that may 
resolve through the cleavage of the second donor strand and gap repair.   
The second model, proposed by Douglas Berg, known as the cut-and-paste 
mechanism (Fig. 3) involves the complete release of the transposon from the donor DNA 
by transposase enzymes without a cointegrate intermediate (as reviewed by Bennet 
1991).  The Berg, cut-and-paste model of conservative transposition, is now widely held 
as the correct mechanism for the simple insertion of many composite transposons and 
insertion sequence elements, including Tn7 and Tn10.  The cut-and-paste model of 
transposition is believed to involve the formation of a nucleo-protein complex, where 
donor and target DNA and several transposase enzymes interact to carry out a strand 
transfer reaction (Bainton, Gamas et al. 1991; Bainton, Kubo et al. 1993; Craig 1995, 
1996; Sarnovsky, May et al. 1996). 
1.11 In-Vivo Versus In-Vitro Transposon Mutagenesis 
 The basic principals behind both in-vivo and in-vitro transposon 
mutagenesis are fundamentally the same:  a transposable element is translocated from one  
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 Fig. 3.  Tn7-based transposon mutagenesis.  For simplicity, the transposase enzymes are 
not shown.  Within a DNA-protein complex, transposase nicks the donor and target 
DNA (solid arrows pointing to gaps), releasing the transposon flanked by insertion 
sequences (IS) and mediates the insertion into the donor and strand transfer reaction.  
The cell’s DNA repair mechanisms fill-in and ligate the gap left by strand transfer, 
which results in the formation of a 5 base pair repeat on both sides of the inserted 
transposon (Maloy et al. 1994). 
 
location to another (with or without replication).  But, as their names imply, the major 
difference between the two lies in whether the transposition reaction occurs 
intracellularly.  With in-vivo transposition, a transposable element is introduced into a 
microorganism, via plasmid, phage, etc., where it either uses the host’s transposition 
 38
machinery or it codes it’s own transposase enzymes for the process of transposition.  In 
this system, the transposon may theoretically choose to insert anywhere in the host’s 
available genome.  In-vivo transposon mutagenesis of Brucella has been used 
successfully for at least 15 years in search of Brucella virulence genes.  Smith and 
Heffron (1987) first mutagenized the Brucella abortus genome using a Tn5-based system 
encoded on a plasmid and on a bacteriophage.  Numerous studies of Brucella spp. 
followed which also employed an in-vivo Tn5-based system (Jumas-Bilak et al. 1998a; 
Foulongne et al. 2000; Hong et al. 2000; Lestrate et al. 2000; Delrue et al. 2001; Endley 
et al. 2001). 
 In contrast to the in-vivo system, in-vitro transposition is a cell-free process.  In-
vitro transposition was first developed by Bainton et al. (1991) to insert a Tn7-based 
transposon into the genome of E. coli.  In order to mimic the intracellular environment, 
the Tn7-based, in-vitro method requires the addition of a target DNA, Mg2+, ATP, and the 
appropriate transposase proteins, TnsA, TnsB, TnsC, and TnsD (Bainton et al. 1991, 
1993; Craig 1996).  Originally, given the appropriate enzymes, Tn7 would preferentially 
insert at specific sites in a genome (attTn7 sites).  However, an artificial mutation in the 
TnsC enzyme has allowed random targeting of a given genome with Tn7 (Stellwagen and 
Craig 1997).  This type of in-vitro mutagenesis system is important for Brucella genetics 
because it now allows targeted transposition of genes that have been cloned into suitable 
vectors.       
1.12 The Current Study 
This thesis describes the application of a rapid, simplified method of gene 
disruption in the genus Brucella known as in-vitro transposition.  The bacterial 
transposon, Tn7, found on a donor plasmid, pGPS3, created by New England Biolabs 
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(Beverly, MA), was used, in-vitro, to insert a selectable marker expressing kanamycin 
resistance into the virB1 gene of B. abortus 2308, which had been cloned by PCR into a 
Brucella suicide vector, pGEM-T.  This construct was then used for the in-vivo 
replacement of the wild type virB1 gene from virulent strains of B. melitensis 16M and B. 
abortus 2308, resulting in null mutations.  The two virB1 mutant strains of Brucella 
created, BM29-106, which was derived from B. melitensis, and BA29-6, which was 
derived from B. abortus, were used to infect murine macrophages and BALB/c mice.  An 
analysis of Brucella mutant survival compared to wild type at several time points was 
then performed.  Reliable gene disruption of the virulence gene virB1 was examined in 
the present study to scrutinize the efficacy of in-vitro, Tn7-based transposition in the 
evaluation of Brucella genes that may hold promise for the development of vaccine 
strains of Brucella. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Bacterial Strains, Plasmid Vector Construction and Growth Conditions   
Original Brucella strains used in this study include B. melitensis 16M and B. 
abortus 2308 obtained from Dr. Elzer of the Department of Veterinary Science at 
Louisiana State University (Baton Rouge) (Table 4).   
Table 4.  Bacterial strains and plasmids used in this work. 
 
Strains or plasmids Relevant characteristic(s)          Source 
Strains   
   Brucella melitensis 16M Wild type, virulent, smooth Elzer 2002b 
   Brucella abortus 2308 Wild type, virulent, smooth Elzer 2002b 
   BA29-6 B. abortus 2308 virB1 mutant, AmpS, 
KanR   
This work 
   BM29-106 B. melitensis 16M virB1 mutant, AmpS, 
KanR   
This work 
   Escherichia coli DH5α-MCR Host for pGEM-T and its derivatives Invitrogen 
(Carlsbad, CA)
Plasmids   
   pBBR1MCS Broad-host-range cloning vector, CmR Elzer 2002b 
   pBBR1MCS::kan Tn7-based, kanamycin transposon from 
pGPS3 transposed into pBBR1MCS 
This work 
   pGEM-T Gram-negative host cloning vector Promega 
   pGEMT-virB1 0.75 kb virB1 PCR product from B. 
abortus 2308 cloned into pGEM-T 
 
This work 
   pBAvirB1::kan-29 Tn7-based, kanamycin transposon from 
pGPS3 transposed into the virB1 gene 
of pGEMT-virB1 
This work 
 
All brucellae were grown in one of the following media: 1) Brucella broth (Difco 
Laboratories, Detroit, MI), 2) Tryptic Soy Broth (TSB) (Difco Laboratories), or 3) SOC-
B media (6% TSB, 10mM NaCl, 2.5mM MgCl2, 10mM MgSO4, 20mM glucose, pH to 
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6.8-7.0) at 370C with constant shaking.  Solid media used for Brucella culture included 
Schaedler Agar (SBA) (BBL/Becton Dickinson, Cockeysville, MD) plates supplemented 
with 5% defibrinated bovine blood and incubated at 37oC in a 5 % CO2 atmosphere.   
Inoculation doses for each strain were prepared as previously described (Elzer et 
al. 1994).  Escherichia coli DH5α-MCR (Table 4) were grown on Luria Butani (LB) 
media (10g tryptone, 5g yeast extract, 5g NaCl per 1000ml H20) + 1.5% agar at 370C or 
in LB broth at 370C with constant shaking.  When appropriate, the following antibiotics 
or chemicals were added to the following final concentrations:  kanamycin 50 µg/ml 
(Sigma, Chemical Co., St. Louis, MO); ampicillin 100 µg/ml (Sigma); chloramphenicol 
30 µg/ml (Sigma); IPTG 0.5mM (Amresco, Solon, OH); X-Gal 80 µg/ml (Amresco).  
The E. coli compatible cloning vector pGEM-T (Table 4) was used to construct plasmids 
containing the virB1 gene of B. abortus 2308 as per the manufacturer’s instructions.  The 
broad host range vector pBBR1MCS (Table 4) that carries a chloramphenicol resistance 
gene (CmR) was also obtained from Dr. Philip Elzer of LSU (Kovach et al. 1994).      
2.2 Isolation and Preparation of Brucella DNA 
For Brucella chromosomal DNA isolation, 5-10ml TSB was inoculated with the 
appropriate species of Brucella and grown overnight with shaking at 37oC.  The culture 
was pelleted and resuspended in 300µl of phosphate buffered saline (PBS).  An 
equivalent volume of chloroform was added and the entire tube was mixed on a rocker 
for 30-60 minutes.  One hundred seventy five microliters of 50mg/ml lysozyme 
(Invitrogen) was added and allowed to sit, with occasional mixing, for 30-60 minutes at 
37oC.  Three microliters of 20mg/ml proteinase K (Invitrogen) was added and incubated 
for 30-60 minutes at 37oC.  Ten percent sodium dodecyl sulfate (SDS) (Sigma) was 
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added to a final concentration of 1% and incubated at 65oC for 5 minutes with occasional 
mixing.  An equal volume (500ul) of phenol:chloroform (25:24 ratio) (Sigma) was added 
and mixed well but gently.  This mixture was centrifuged at 10,000 x g for 5-10 minutes.  
The upper layer was removed with a wide bore 200µl pipette tip and extracted a second 
time with an equal volume of phenol:chlorform.  After the second phenol:chloroform 
extraction, an equal volume of chloroform was added, the mixture was centrifuged at 
10,000 x g for 2 minutes and the chloroform was removed and discarded.  A 1/10 volume 
of 3M sodium acetate (Sigma) plus a 2X volume of 95% ethanol was added and allowed 
to precipitate overnight at –20oC.  The mixture was centrifuged and the liquid was 
decanted or pipetted out and discarded.  The Brucella DNA was resuspended in 500µl 
Tris-EDTA (TE), pH 8.0, and treated with 10µl of 50mg/ml RNaseA (Invitrogen) for 1 
hour at 37oC.  A 1/10 volume of 3M sodium acetate plus a 2X volume of 95% ethanol 
was added and the DNA was allowed to precipitate overnight at –20oC.  The mixture was 
centrifuged and the liquid was decanted or pipeted out and discarded.  The DNA was 
resuspended in 300-500µl TE.  Brucella DNA yield was typically 150-300 mg/ml per 
isolation.  
2.3 Transposon Mutagenesis and Creation of Suicide Plasmid 
The Tn7 based GPS-Mutagenesis System (New England Biolabs) was used, 
according to the protocol provided, to insert a KanR cassette randomly into pBBR1MCS.  
Mutagenized pBBR1MCS (pBBR1MCS::kan) was transformed into E. coli DH5α-MCR 
cells as described in the Invitrogen transformation protocol.  Transformants carrying the 
plasmid pBBR1MCS::kan were selected on LB + kanamycin (50 µg/ml) + 
chloramphenicol (30 µg/ml).  Plasmid DNA was isolated by the alkaline lysis method 
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(Sambrook et al. 1989) and by using a plasmid miniprep kit (Qiagen-Operon, Valencia, 
CA) and suspended in sterile, deionized H2O.  The virB1 gene fragment from B. abortus 
2308 was generated by the polymerase chain reaction (PCR) using virB1F and virB1R 
primers (Table 5) and ligated, with DNA ligase, into the plasmid vector pGEM-T at a 1:1 
molar ratio of virB1 PCR product to pGEM-T vector following the protocol provided by 
Promega.  
Table 5.  Primers used for PCR and sequencing 
 
Primer Sequence 
virB1F 5’-AGGAGACGATCCTATGGTGC-3’ 
virB1R 5’-GTGCCTGATCGGATGATGG-3’ 
N-primer 5’-ACTTTATTGTCATAGTTTAGATCTATTTTG-3’ 
S-primer 5’-ATAATCCTTAAAAACTCCATTTCCACCCCT-3’ 
AmpF 5’-TCATCCATAGTTGCCTGACTCC-3’ 
AmpR 5’-GTATTCAACATTTCCGTGTCGC-3’ 
 
The PCR parameters for virB1 amplification using virB1F and virB1R are given 
below (Table 6).  The virB1 PCR product plus vector, pGEM-T + virB1 (pGEMT-virB1), 
was transformed into E. coli DH5α-MCR cells and 100-200 µl of the transformantion 
mixture was plated on LB + 1.5% agarose plates containing ampicillin (100µg/ml) + 
IPTG (0.5mM) + X-Gal (80µg/ml).  After incubation for 10-24 hours at 37oC, white 
colonies were chosen as successful recombinants which were inoculated into LB broth + 
ampicillin (100 µg/ml) and grown overnight.  One and a half milliliters of each broth 
culture was centrifuged for 30 seconds at 10,000 x g and plasmids were isolated using the 
Qiagen-Operon plasmid miniprep kit.  Purified plasmids were suspended in sterile, 
deionized H2O.  Correct virB1 insertion into pGEM-T was confirmed by restriction 
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endonuclease digestion of purified plasmids using the restriction enzyme RsaI (New 
England Biolabs). 
Table 6.  PCR conditions used with the virB1 and Amp primers 
 
  Time (min) Temperature (oC) Repeat 
0:30  95 1X 
0:30 95 
0:30 58 
2:00 72 
30X 
10:00 72 1X 
∞ 4 Holding 
Temp 
 
Correct forward or reverse insertion gave the following size bands when run in a 1% 
agarose gel for one hour at 90 V and stained with ethidium bromide (0.3 µg/ml) (Sigma):  
Forward insertion = 1414 and 2336 base pairs; Reverse orientation insertion = 1686 and 
2064 base pairs (Fig. 4).   
Ten plasmids were chosen and reconfirmed by restriction with BsgI (New 
England Biolabs); correct banding pattern after restriction, indicating a forward insertion 
= 3381 and 370 base pairs.  Confirmed pGEMT-virB1 plasmid DNA concentration was 
measured with a Pharmacia Biotech, UV/Visible spectrophotometer.  One microgram of 
the confirmed pGEMT-virB1 plasmid was mutagenized using the GPS-M transposon 
system according to the protocol provided with the kit.  One microliter and 10µl of the 
mutagenesis reaction were transformed into E. coli DH5α-MCR cells, plated on LB + 
kanamycin (50 µg/ml) and incubated overnight at 37oC.  Transformants carrying the 
plasmid pGEM-T + virB1 + pGPS3 (pBAvirB1::kan) were selected on LB agar plates + 
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kanamycin (50 µg/ml).  Plasmid DNA was isolated by the alkaline lysis method and by 
using the Qiagen-Operon plasmid miniprep kit and suspended in sterile, deionized H2O.   
pGEM-T
virB1
RsaI
RsaI
Forward orientation insertion
Restriction 
with RsaI
1414 base pairs
2336 base pairs
virB1
RsaI
RsaI
Restriction 
with RsaI
1686 base pairs
2064 base pairs
Reverse orientation insertion
 
  
Fig. 4.  Possible restriction products after virB1 insertion into pGEM-T. 
 
Plasmids were screened for the correct restriction pattern by restriction 
endonuclease digestion indicating a possible 1700 base pair Tn7 cassette insertion into 
virB1 using the restriction enzymes Nco I and Pst I (New England Biolabs).  The 
restriction pattern for a possible Tn7 insertion into virB1, after electrophoresis in a 1% 
agarose gel and staining, consisted of two bands, 2485 and 2964 base pairs, while Tn7 
insertion into pGEM-T would have been seen as bands of 785 and 4664 base pairs (Fig. 
5).  PCR was performed on plasmids that gave the correct restriction pattern using the 
virB1F and virB1R primers under the previous PCR parameters (Table 6).  PCR reactions 
giving the correct band size of 2450 base pairs, after being run in a 1% agarose gel and 
ethidium bromide staining (0.3 µg/ml) were used as templates for a sequencing reaction.  
Sequencing was carried out by the di-deoxy method using a premixed sequencing reagent 
(United States Biochemical/Amersham Life Sciences, Cleveland, OH).  Primers N and S, 
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which are provided by New England Biolabs with the pGPS3 mutagenesis system, were 
used for sequencing under the PCR conditions given in Table 7.   
 
pGEM-T
virB 1
NcoI
Tn 7 insertion into virB 1
Restriction with 
NcoI and PstI
2485 base pairs
2964 base pairs
785 base pairs
4664 base pairs
Tn 7 insertion into pGEM-T
KanR
PstI
KanR
NcoI
Restriction with 
NcoI and PstI
KanR
PstI
virB 1
virB 1
KanR
 
Fig. 5.  Possible restriction products after Tn7 insertion into pGEMT-virB1. 
 
Primers N and S anneal at the ends of the pGPS3 KanR transposon and face out 
into the gene of interest.  The result of sequencing for a successful Tn7 insertion was 
plasmid #29 (pBAvirB1::kan-29).   
Table 7.  Sequencing PCR conditions used with the N and S primers. 
 
Time (min) Temperature (oC) Repeat 
1:00  96 1X 
0:10 96 
0:05 50 
4:00 60 
25X 
∞ 4 Holding 
Temp 
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2.4 Electroporation and Gene Replacement   
In preparation for electroporation, brucellae were grown in TSB overnight at 37oC 
with constant, gentle shaking, centrifuged and washed 3X in ice cold, sterile deionzed 
H20.  The plasmids pBBR1MCS::kan and #29 were introduced into B. abortus 2308 and 
B. melitensis 16M by electroporation at 2500 volts with an Eppendorf, Corp. 
electroporator (Hamburg, Germany; model 2510).  For most transformations, 1µg 
plasmid DNA was added to 33µl (1x108 cfu/ml) of brucellae.  Immediately after 
electroporation 500µl of SOC-B was added to the transformation broth and the brucellae 
were allowed to recover overnight at 37oC with constant, gentle shaking.  Successful 
transformants were chosen after plating on SBA + kanamycin (50 µg/ml) and incubation 
at 37oC in a 5% CO2 atmosphere.    
Brucellae that underwent successful crossover between the mutated virB1 region 
found on the electroporated plasmid #29 and the Brucella wild type virB1 gene, exhibited 
ampicillin sensitivity (AmpS) and KanR.  This was confirmed by isolating chromosomal 
DNA from the KanR brucellae and performing PCR using the previous virB1 primers.  
Visualization of this PCR product from transformed brucellae on a 1% agarose gel gave 
only the long product of 2450 base pairs (virB1+pGPS3 KanR transposon).  The 
restriction endonuclease Hind III was used to digest the amplified virB1 fragment giving 
the expected band sizes of 1280 and 1170 base pairs after electrophoresis in a 1% agarose 
gel (Fig. 6).  A sequencing reaction was run of the mutant virB1-amplified fragments 
from both suspected Brucella mutant strains, B. melitensis 16M mutant BM29-106, and 
B. abortus 2308 mutant BA29-6.  The virB1 portion of both mutant sequences matched 
the existing virB1 sequence of B. abortus 2308 in Genebank. 
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PCR of Brucella chromosomal DNA using 
virB 1F and virB 1R
KanR
HindIII
Long amplicfication 
product of 2450 bp 
(virB 1::kan)
Restriction with 
HindIII
virB 1
1280 base pairs
virB 1
virB 1
1170 base pairs
 
Fig. 6.  Confirmation of virB1::Tn7 insertion by the amplification of virB1::Tn7 from 
Brucella chromosomal DNA and restriction with HindIII. 
 
2.5 Murine Phagocyte Killing Assay   
Murine macrophages were harvested in the following manner.  Twenty week-old 
BALB/c mice were euthanized by a halothane overdose and the peritoneal body cavity 
was exposed by peeling back the skin on their abdomens.  Using a 6cc syringe with a 
1.5”, 22 gauge needle, 4 mls of media + 1ml of air was injected into the peritoneum at the 
mid-belly region.  The injected media was a combination of Minimum Essential Eagle 
Media (MEM) (Sigma) + 5% Fetal Calf Serum (FCS)(Sigma) + Heparin 
(5U/ml)(Invitrogen).  After media injection, the mouse was shaken vigorously for 1 
minute and the media containing peritoneal macrophages was drawn out.  The 
macrophages were centrifuged for 5 minutes at 1100 rpm and 4oC and the resulting pellet 
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was resuspended in 1ml of MEM media per mouse used for harvest.  Viability counts 
were performed by staining 100µl of macrophages with 100µl trypan blue in 800µl of 
MEM media and visual counting with a hemocytometer leading to a final stock dilution 
of 5x106 cells/ml.  One hundred microliters of macrophages were placed in each well of a 
96 well plate (5x105 cells/well) and allowed to adhere (differentiate) overnight.  The next 
morning, macrophages were washed 3X with 200µl of warm PBS + 0.5% FCS to remove 
non-adherent cells.  After the last washing, 200µl of warm MEM + 5% FCS was added to 
each well.  For opsonization, FCS + mouse antibodies were added at 1µl per ml of cells, 
to 1x108 Brucella in MEM and incubated for 30 minutes at 37oC.  Two hundred 
microliters of opsonized brucellae were added to each well containing macrophages and 
incubated for 2 hours at 37oC.  The macrophages were washed once with MEM media 
and twice with PBS-0.5 % FCS.  Two hundred microliters of MEM + gentamycin 
(50µg/ml) (Sigma) was added to each well and incubated at 37oC for 45 minutes to 1 
hour.  Macrophages in each well were washed 2X with PBS/FCS and reincubated with 
MEM + gentamycin (12.5µg/ml).  For each time point investigated, T0, T24 and T48 hours, 
the gentamycin was washed out and deoxycholate (Sigma) was added to a final 
concentration of 0.1% to lyse all macrophages.  Each well was diluted with 20-180µl 
PBS and plated on SBA or SBA + kanamycin (50 µg/ml).  Plates were incubated for 2-3 
days at 37oC in a 5% CO2 atmosphere. 
2.6 Mouse Infection Assay 
Both male and female BALB/c mice at 6 weeks of age were challenged 
intravenously with 5x104 cfu of parental strain (B. abortus 2308 or B. melitensis 16M) or 
mutant (BA29-6 or BM29-106).  Infectious doses were confirmed by serial dilution 
followed by plating on SBA for wild type brucellae and SBA + kanamycin (50 µg/ml) for 
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Brucella mutants.  Brucella in-vivo survival was assessed at 1 week and 4 weeks when 
half the mice were euthanized at each time point by halothane overdose and the whole 
spleen was aseptically removed.  The spleen was weighed, homogenized, serially diluted 
and plated on SBA or SBA + kanamycin (50 µg/ml).  Plates were incubated at 37oC in a 
5% CO2 atmosphere for 3 days. 
2.7 Primers  
Primers for amplification of virB1 from Brucella chromosomal DNA include 
virB1F and virB1R that were supplied by Qiagen-Operon.  The B. abortus and B. 
melitensis virB1 sequences differ by only 1 base pair, therefore, virB1 primers were 
chosen based on the published sequence of virB1 of B. abortus in GeneBank (Genebank 
accession number AF226278).  Primers AmpF and AmpR were also supplied by Qiagen-
Operon.  Primers N and S were provided by New England Biolabs for use with the GPS-
M mutagenesis system.   
2.8 Biochemical Identification Tests   
Brucella virB1 mutants and parental strains were characterized with standard 
biochemical identification tests (Table 8).  All virB1 Brucella mutant strains were 
Table 8.  Results of biochemical identification tests on BM29-106, BA29-6, B. abortus 
2308 and B. melitensis 16M. 
 
Test B. abortus 2308 B. melitensis 16M BA29-6 BM29-106 
Oxidase + + + + 
Urease + + + + 
Gram Stain - - - - 
 
biochemically identical to their original parental species.  Biochemical identification tests 
on BM29-106, BA29-6, B. abortus 2308 and B. melitensis 16M included the following:  
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oxidase (BBL/Becton Dickenson), urease (LSU School of Veterinary Science Media Lab, 
Baton Rouge, LA), and Gram stain (Becton Dickson, Sparks, MD).   
2.9 Statistical Analyses 
 For statistical comparison of two independent samples at a single time point the 
student two-sample, paired t-test was used (Graphpad Instat, version 3.05).  This test was 
utilized in the analysis of Brucella virB1 mutant versus non-mutant survival in both the 
macrophage-killing assay and the in-vivo mouse assay examining Brucella survival.   
In addition, the two-sample t-test was employed for statistical assessment of virB1 mutant 
versus non-mutant splenic weight due to Brucella burden.  For all statistical tests, a 
confidence interval of 95% (P<0.05) was considered significant. 
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CHAPTER 3. RESULTS 
3.1 Complementation of Brucella with pBBR1MCS::kan  
The ability of brucellae to exhibit resistance to the antibiotic kanamycin after 
complementation with a kanamycin resistance gene has been established previously in 
several studies (O'Callaghan et al. 1999; Foulongne et al. 2000; Hong et al. 2000; 
Sangari, Aguero et al. 2000; Sieira et al. 2000).  However, it was necessary to confirm 
that the promotor, which precedes the kanamycin resistance cassette on the transposon in 
pGPS3, demonstrates reliable expression within Brucella.  The broad host range vector 
pBBR1MCS, which is stably maintained within all Brucella species, was mutagenized 
with the GPS-Mutagenesis system giving the plasmid pBBR1MCS::kan.  This construct 
was then transformed by electroporation into B. melitensis 16M and B. abortus 2308 
(Kovach et al. 1994; Elzer et al. 1995).  The pGPS3 donor backbone contains a gene 
conferring ampicillin resistance while pBBR1MCS contains a chloramphenicol resistance 
gene.  Successful mutagenesis, without pGPS3 backbone integration, transformation of 
the plasmid into Brucella, maintenance and antibiotic gene expression was confirmed 
when B. abortus 2308 and B. melitensis 16M were plated on SBA and the appropriate 
antibiotics.  Stable maintenance was displayed by colonies that exhibited sensitivity to 
ampicillin (AmpS), resistance to chloramphenicol (CmR) and KanR (data not shown). 
3.2 Creation of virB1 Brucella Mutants   
A suicide plasmid was created to replace virB1 in Brucella species.  This plasmid 
is composed of the B. abortus 2308 gene virB1 that has been ligated into the cloning 
vector pGEM-T, and mutagenized by insertion of a Tn7 based kanamycin resistance 
cassette generating the plasmid pBAvirB1::kan-29 (Fig. 7).   
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lacZ
   virB 1
f1 ori
AmpR
   Tn 7-based transposon  
(KanR)
       pBAvirB 1::kan-29 
   Suicide vector
         (5449 bp)
ori
 
Fig. 7.  Brucella suicide vector, pBAvirB1::kan-29, constructed by inserting a kanamycin 
resistance cassette into the virB1 gene of Brucella which had been cloned into the 
vector pGEM-T. 
 
The virB1 gene contained on this plasmid is that of B. abortus 2308, which is 
almost identical (one base pair difference) in sequence to the virB1 gene of B. melitensis 
16M.  Transformation of B. melitensis 16M and B. abortus 2308 by electroporation with 
pBAvirB1::kan-29 resulted in the isolation of KanR, virB1 mutant colonies which were 
named BM29-106 and BA29-6 respectively.  The designation of “29” in strain 
nomenclature serves only to further classify which mutant plasmid was employed in gene 
replacement, while the numbers “-106” and “-6” give the particular mutant colony from 
which the strain was cultured.  These two strains exhibited AmpS, verifying that the 
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pGEM-T backbone, which contains an ampicillin resistance gene, was not incorporated 
into the Brucella genome.   
To confirm a double cross-over event and replacement of the Brucella wild type 
virB1 gene with virB1::kan-29, PCR was performed on chromosomal DNA isolated from 
the suspected Brucella mutants, BM29-106 and BA29-6.  The size of these PCR products 
was then determined by electrophoresis on a 1% agarose gel, staining with ethidium 
bromide and exposure to UV light (Fig. 8).  The mutant virB1 PCR amplification 
products were then compared to the amplification products for wild-type virB1 from B. 
melitensis 16M and B. abortus 2308 using the previously employed virB1 primers.  When 
amplified with the virB1 primers, the wild type virB1 genes of B. melitensis and B. 
abortus are 750 base pairs in length (lanes 6 and 7 respectively).  Once the wild type 
virB1 gene of Brucella has been mutagenized with the Tn7-based transposon, which is 
1700 base pairs long, the virB1 amplification product increases in length by 1700 base 
pairs to 2450 base pairs.  As seen in Fig. 5, the resulting bands of 2450 base pairs for the 
virB1 mutant strains, BM29-106 and BA29-6, (lanes 3 and 4 respectively) correspond to 
the disrupted virB1 genes containing the additional 1700 base pair transposon.   
Lane 2 contains a virB1 PCR product of 2450 base pairs from the suicide plasmid 
used for gene replacement, pBAvirB1::kan-29, which serves as a positive control 
indicating the correct length of a Tn-7-mutated virB1 gene.  Nucleotide sequencing of 
both 2450 base pair, mutant virB1 PCR products from BM29-106 and BA29-6 confirmed 
their identity as virB1 containing a Tn7-based transposon (Data not shown).  Primers used 
for sequencing included primer N and S, which were supplied by New England Biolabs 
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with the GPS-Mutagenesis system.  These primers anneal at the ends of the Tn7-based 
transposon and extend out into the gene that has been disrupted. 
3000 bp
2000 bp
2450 bp
850 bp
   750 bp
650 bp
Lane                       1             2              3              4              5              6              7             8
 
 
Fig. 8.  One percent agarose gel showing PCR amplification of virB1 from BM29-106 
(lane 3), BA29-6 (lane 4), B. melitensis 16M (lane 6), B. abortus 2308 (lane 7), and 
pBAvirB1:kan-29 (lane 2).  The virB1 gene of both mutant strains and 
pBAvirB1::kan-29 is 2450 base pairs while both parental strains contain the wild type 
virB1 of 750 base pairs.  A 1 kb plus DNA ladder is provided in lanes 1, 5 and 8 
(Invitrogen). 
 
Sequencing, employing the N and S primers, reveals that the pGPS3 transposon was 
inserted between base pairs 909 and 910 of the B. abortus 2308 wild type virB1 gene 
(Genebank accession number AF226278).   
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 To further ensure the ampicillin containing, vector backbone of pBAvirB1::kan-
29 was not integrated into either the B. melitensis or B. abortus genome with the virB1 
gene, PCR was performed on chromosomal DNA isolated from the mutants BM29-106 
and BA29-6, using primers for the ampicillin resistance gene, AmpF and AmpR, as well 
as a combination of N or S primers and virB1F and virB1R primers (Fig. 9).   
Lane               1               2              3               4              5               6               7               8               9             10
 1000bp
   800bp
  650bp
  3000bp
  2400bp
  2000bp
 
Fig. 9.  One percent agarose gel showing PCR amplification of ampicillin gene from:  
pBAvirB1::kan-29 (lane 1) using ampicillin primers (Amp product size 800bp), B. 
abortus 2308 virB1 mutant (lanes 2, 4 and 5) and B. melitensis 16M virB1 mutant 
(lanes 6, 7 and 8) using both Amp primers (lanes 2 and 6) and one Amp primer with 
either N or S primer (lanes 4-5 and 6-7).  Lane 9 shows PCR of pBAvirB1::kan-29 
using one Amp primer (reverse) and the N primer (2400bp).  Lanes 3 and 10 contain 
a 1kb+ DNA ladder (Invitrogen). 
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No resulting bands were seen in lanes 2, 4, 5, 6, 7, and 8, which would be indicative of 
vector integration using genomic DNA from BM29-106 and BA29-6.  As positive 
controls, the original suicide plasmid pBAvirB1::kan-29, which contains an ampicillin 
resistance gene, was PCR amplified using the AmpR and AmpF primers (lane1) and 
using the AmpR primer and N primer in conjunction (lane 9).  All PCR products were 
run on a 1% agarose gel, stained with ethidium bromide and exposed to UV light.      
3.3 Increased Brucellacidal Activity of Murine Macrophages Against virB1 Mutants  
To assess whether a nonfunctional virB1 gene will cause B. abortus and/or B. 
melitensis to become more susceptible to the bactericidal activities of the murine 
macrophage, a series of murine phagocyte killing assays were run.  Isolated murine 
macrophages were infected with BM29-106, BA29-6, B. abortus 2308 and B. melitensis 
16M at a ratio of 100 brucellae per macrophage in 96 well plates.  At time points of 0, 24 
and 48 hours, infected macrophages were lysed, their intracellular brucellae were serially 
diluted, plated on SBA and incubated at 37oC in a 5% CO2 atmosphere.  Results of these 
experiments are represented graphically in Fig. 10.  The differences between both 
parental and mutant strains of Brucella were statistically significant at a confidence 
interval of at least 95% (P<0.05) for both time points (24 and 48 hours).  The disparity 
between B. melitensis 16M and BM29-106 intracellular survival increased steadily over 
48 hours.  Compared to wild type B. melitensis 16M, BM29-106 survival decreased 
rapidly by 24 hours post-infection (t=24) to a level 73% lower than the wild type 
(P<0.01, n=6), and by 48 hours (t=48), BM29-106 intracellular survival had fallen >98% 
below wild type B. melitensis (P<0.01, n=6).   
A similar pattern was observed between B. abortus 2308 and its virB1 mutant, 
BA29-6, for which every mean comparison was statistically significant.  By 24 hours  
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Fig. 10.  Results of the murine macrophage killing assay assessing the survival of BM29-
106 (box) and BA29-6 (star) versus their parental strains, B. melitensis 16M 
(diamond) and B. abortus 2308 (triangle) over a period of 48 hours. 
 
post-infection (t=24) the average wild type B. abortus survival rate was 10% greater than  
for its mutant, BA29-6 (P<0.05, n=6).  By 48 hours post-infection (t=48), the average 
BA29-6 population had dropped to 98% of wild type B. abortus 2308 (P<0.01, n=6).     
3.4 Virulence and Survival of Brucella virB1 Mutants in the Mouse Model 
To assess the virulence of virB1 Brucella mutants and the capacity of the virB1 
mutant strains to survive within a mammal host, 40 5-week old BALB/c mice were 
intravenously infected with B. abortus 2308, B. melitensis 16M, BM29-106, and BA29-6.  
Half the mice in each category (5 mice/category) were euthanized at 1 week while the 
other half were euthanized at 4 weeks.  This resulted in two time points for each strain of 
Brucella, each containing 5 mice.  Necropsy at both time points involved aseptic removal 
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of the spleen, which was then weighed, homogenized, serially diluted and plated on SBA 
for Brucella viability counting.   
3.4.1 Spleen Mass  
The average change in mass of a mouse spleen as a function of time of necropsy 
for each strain of Brucella used for initial infection was calculated (Fig.11).   
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Fig. 11.  Average mouse spleen mass assessing the virulence of each Brucella strain as a 
function of the time post-infection.  B. abortus 2308 (triangle), BA29-6 (star), B. 
melitensis 16M (diamond) and BM29-106 (box). 
 
According to the data, spleen mass for mice infected with B. abortus 2308 and B. 
melitensis 16M wild types was greater than for mice infected with the virB1 mutants 
BA29-6 and BM29-106 at both 1 and 4 weeks.  Student t-tests comparing the spleen mass 
of mice infected with wild type brucellae versus virB1 mutants for each time point were 
statistically significant at a confidence interval of 95% (P<0.05):  B. abortus 2308 
average spleen mass was 87% greater than BA29-6 at 1 week (P<0.01, n=5) and 135% 
greater at 4 weeks (P=0.001, n=5); average spleen mass for B. melitensis 16M was 78% 
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greater than BM29-106 at 1 week (P<0.0001, n=5) and 190% greater at 4 weeks 
(P<0.001, n=5).  In addition, the average spleen mass for the B. melitensis 16M infected 
mice from 1 to 4 weeks increased 81% and was statistically significant, (P<0.01, n=5), 
while the spleen mass of BM29-106 infected mice did not significantly increase (an 11% 
increase).  Spleen mass for B. abortus 2308 infected mice did increase 5% from 1 to 4 
weeks, which was not statistically significant; however, BA29-6 spleen mass decreased 
17% over the same period at a statistically significant level (P<0.05, n=5).      
3.4.2 Spleen Brucella Burden 
The average mouse spleen Brucella burden for each of the 4 Brucella strains is 
graphically represented in Fig. 12 as Brucella colony forming units (cfu) per spleen.   
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Fig. 12.  Results of the in-vivo mouse model of Brucella infection assessing the survival 
of BM29-106 (box) and BA29-6 (star) versus their parental strains, B. melitensis 16M 
(diamond) and B. abortus 2308 (triangle) in-vivo over a period of 4 weeks. 
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The mean cfu/spleen for both virB1 mutants, BM29-106 and BA29-6, was considerably 
below (1.4 to 2 logs lower) their parental counterparts by 4 weeks post-infection and 
statistically significant (P<0.05, n=5) at both time points.  As represented in the graph, a 
comparison between B. melitensis 16M and BM29-106 spleen colonization reveals that at 
1-week post-infection, BM29-106 colonized the mouse spleen at a statistically significant 
lower level, 0.68 logs less than its parental strain (P<0.05, n=5).  The gap between these 
two strains, in regards to spleen Brucella burden, increaseed at 4 weeks to 1.4 logs, which 
maintained statistical significance (P<0.05, n=5).  The disparity between B. abortus 2308 
and its virB1 mutant counterpart, BA29-6, was even greater at both time points.  Analysis 
reveals that at 1-week post-infection the splenic colonization of the B. abortus 2308 virB1 
mutant (BA29-6) was 0.82 logs less than its parental strain, which is statistically 
significant (P<0.01, n=5).  By 4 weeks post-infection BA29-6 remained at a statistically 
significant lower level (2.06 logs lower) in the mouse spleen than wild type B. abortus 
2308 (P<0.01, n=5).    
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CHAPTER 4. DISCUSSION 
4.1 Experiment Summary 
 The mechanisms of Brucella survival and virulence are not fully understood.  The 
success of Brucella, however, appears to be a product of its ability to endure and thrive in 
the normally bactericidal environment of the phagocyte.  Many of the past studies into 
the novel mechanisms that allow Brucella this environmental niche have relied upon the 
creation of null mutations.  At least two methods have been employed in the construction 
of null mutations leading to Brucella knockout strains:  In-vivo, random transposition 
using Tn5-based transposons, and in-vitro gene disruption by insertion of a selectable 
marker at an endonuclease restriction site.  A third method of gene mutation, performed 
in-vitro, is presented in the current study.  GPS-M is a Tn7-based, in-vitro transposition 
system designed by New England Biolabs for the targeted inactivation of genes with a 
kanamycin resistance cassette that can be used in Gram-negative organisms.  This thesis 
described the use of the GPS-M system for insertional mutation of a Brucella virulence 
gene, virB1.   
 The central aim of this study was to investigate the efficiency and utility of an in-
vitro, Tn7-based transposition system for the inactivation of genes within members of the 
genus Brucella.  Initially, the plasmid pBBR1MCS, which is stably maintained in all 
Brucella species (Elzer et al. 1995), was mutagenized by the insertion of a Tn7-based 
transposon containing a kanamycin resistance cassette producing the plasmid 
pBBR1MCS::kan.  Expression of kanamycin resistance by Brucella indicated the reliable 
functioning of the foreign, Tn7-based promotor within brucellae.  The virulence gene 
virB1, found in B. melitensis 16M and B. abortus 2308, was then cloned into a vector 
where it also was mutagenized by the insertion of a Tn7-based transposon, creating the 
 63
suicide plasmid pBAvirB1::kan-29.  This construct was used successfully to replace the 
wild-type virB1 gene in-vivo by homologous recombination, generating virB1 mutant 
strains of B. melitensis 16M (BM29-106) and B. abortus 2308 (BA29-6).  PCR and 
nucleotide sequencing confirmed disruption of the B. melitensis and B. abortus virB1 
loci.   
 The efficacy of gene inactivation via in-vitro transposition and the pathologic 
significance of the Brucella virB1 gene were evaluated by infection of murine peritoneal 
macrophages and BALB/c mice with the virB1 mutants BM29-106, BA29-6 and their 
parental strains.  Results of these experiments suggest that in-vitro Tn7-based 
transposition is an effective method for the creation of null mutations.  Both virB1 mutant 
strains exhibited attenuated virulence and lower levels of survival compared to wild type 
B. melitensis 16M and B. abortus 2308 in both the macrophage and murine models.  The 
survival of Brucella mutants in both models and at all time points were significantly 
lower (P<0.05) than wild type.  
4.2 virB1 Mutation in Other Species Results in Attenuation of Virulence 
Several studies have investigated the significance of the virB operon to the 
pathogenicity of Brucella (O'Callaghan et al. 1999; Ugalde 1999; Foulongne et al. 2000; 
Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001; Delrue et al. 2001; Boschiroli et 
al. 2002), however, most of what is known about the virB operon has come from work 
with other type IV secretion systems, especially the Agrobacterium virB complex.  In 
mutational studies with Agrobacterium, a plant parasite that causes crown gall disease, 
Berger and Christie (1994) discovered that virB1 is a non-essential virulence factor or 
transport component for eukaryotic cell transformation (Christie 1997; Christie and 
Covacci 2000).  While non-polar mutations of virB2-virB11 resulted in avirulent strains 
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of A. tumefaciens, mutation of only virB1 decreased the efficiency of DNA transfer from 
bacterium to plant by 1 to 3 orders of magnitude compared to bacteria with a wild type 
virB1 gene (Berger and Christie 1994; Fullner 1998).  Similar results (10-100 fold 
decrease in conjugation or transfer frequency) were found in other virB1 relatives: “gene 
19” of plasmid R1 (Bayer, Eferl et al. 1995) and traL of plasmid pKM101 (Winans 1985 
as cited in Berger and Christie 1994; Pohlman et al. 1994; Baron, Llosa et al. 1997).  As 
asserted by Baron et al. (1997), this decrease in virulence, as opposed to complete 
avirulence, may signal that transglycosylase-like activities are not essential for functional 
type IV machinery, or that there are redundant systems present (Boschiroli et al. 2002).  
In support of this theory, the type IV secretion systems of Bartonella henselae 
(Schmiederer, Arcenas et al. 2001), Legionella pneumophila, Bordetalla pertussis, 
Rickettsia provawekii, IncW plasmid R388 and Helicobacter pylori (Bayer et al. 1995; 
Baron et al. 1997; O'Callaghan et al. 1999; Segal, Russo et al. 1999; Christie and Covacci 
2000; Sieira et al. 2000) lack a virB1 homologue entirely.  And in the case of B. 
melitensis 16M, a membrane-bound lytic murein transglycosylase is encoded on 
chromosome II immediately before the virB operon (DelVecchio et al. 2002). 
Apart from sequence and protein similarity, it is not known to what extent the 
Agrobacterium and Brucella VirB1 proteins are homologous.  For instance, VirB1 of 
Agrobacterium, after translational processing, produces 2 proteins, VirB1 and VirB1*, 
believed to have independent properties:  1) protein VirB1 is a transglycosylase which 
cleaves the glycosidic bonds of peptidoglycan to create a pore for VirB transporter 
assembly (Dijkstra and Keck 1996; Mushegian, Fullner et al. 1996; Baron et al. 1997; 
Christie 1997; Zupan, Ward et al. 1998; Christie and Covacci 2000; Llosa, Zupan et al. 
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2000), while 2) protein VirB1* is secreted outside the bacterial cell and associates with 
the bacterial membrane, VirB9, and possibly the plant cell wall to initiate or participate in 
pilus formation (Baron et al. 1997; Christie 1997; Chumakov and Kurbanova 1998, 1999; 
Llosa et al. 2000).  A comparison of VirB1 homologues in Agrobacterium and E. coli 
reveals that Brucella VirB1 also contains an N-terminal signal sequence cleavage site 
required for export and amino acid motifs consistent with lytic transglycosylases 
(Mushegian et al. 1996; O'Callaghan et al. 1999).  However, there is currently no 
literature that suggests Brucella VirB1 is processed, as is the Agrobacterium VirB1 
homologue, into 2 independent proteins.      
4.3 virB1 Mutation via Tn7-Based Transposition Results in Brucella Attenuation 
In this study, mutation of virB1 with a Tn7-based transposon produced strains of 
Brucella that were attenuated in the murine macrophage model of infection.  In this 
model, at 24 hours post-infection, the survival of the B. abortus virB1 mutant (BA29-6) 
was 90% of its wild type while the B. melitensis virB1 mutant (BM29-106) survival was 
only 27% of its corresponding parental strain.  By 48 hours in the macrophage model 
both mutant survival rates had dropped to or below 2% of their wild types.  The current 
work shows a statistically significant (at least P<0.05) 1-2 log decrease in Brucella 
intracellular survival at 48 hours in the murine macrophage model and by 4 weeks in the 
mouse model when the Brucella virB1 gene is disrupted.  These results are in agreement 
with previous findings (Berger and Christie 1994; Pohlman et al. 1994; Bayer et al. 1995; 
Baron et al. 1997; Fullner 1998) that inactivation of other virB1 homologues 
(Agrobacterium virB1, “gene 19” of plasmid R1, and traL of plasmid pKM101) results in  
a 1-3 log decrease in microbial survival.  This suggests that the B. melitensis 16M and B. 
abortus 2308 virB1 gene products, like the Agrobacterium VirB1 protein, may not be 
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essential for virulence or intracellular survival up to 4 weeks post-infection in the mouse 
model of infection. 
Assuming VirB1 is not involved in cell-macrophage contact or entry but in 
intracellular survival and multiplication, as several studies have suggested (O'Callaghan 
et al. 1999; Hong et al. 2000; Sieira et al. 2000; Comerci et al. 2001; Delrue et al. 2001; 
Rittig et al. 2001; Boschiroli et al. 2002), attenuated strains of Brucella would be more 
susceptible to the bactericidal mechanisms of the phagocyte, and thus give lower 24 and 
48 hour macrophage intracellular survival counts and lower splenic burdens at 4 weeks 
post-infection.  Evaluating both experimental portions of this series, it can be concluded 
that Tn7-based in-vitro transposition is an efficient means for creating mutated strains of 
B. melitensis 16M and B. abortus 2308.  The current virB1 mutant strains of Brucella are 
less virulent/replication efficient compared to their respective wild type species, 
evidenced by their decreased survival in both model systems of infection.  
4.4 The Importance of the Macrophage and Murine Models of Infection 
The macrophage model is important to the understanding of Brucella infection for 
two reasons:  1) Brucellae depend on the protection afforded them by their intracellular 
lifestyle within the relatively long-lived macrophage.  In-vitro studies suggest that serum 
components are able to kill brucellae, particularly in cattle (Enright 1990).  Outside the 
phagocyte, brucellae are exposed to antibodies, especially IgG, that may enhance 
phagocytosis and macrophage brucellacidal activity (Ralston and Elberg 1971 as cited in 
Nicoletti and Winter 1990).  However, bacteremia is considered an important phase of 
Brucella dissemination and the value of complement to in-vivo brucellacidal action is not 
known or well understood.  2) Brucellae exploit macrophages as one of their main 
vehicles of distribution throughout the mammal host.  Brucellae are non-motile, without 
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flagella, pseudopodia or fimbriae, and thus rely on their own phagocytosis and 
dissemination by macrophages.  The murine model of Brucella infection has been 
demonstrated to be important because experimental results obtained with mice are 
frequently applicable to humans and especially to ruminants such as cows, goats and 
sheep, which are the main reservoirs of several Brucella species (FAO/WHO 1986). 
4.5 Tn7-Based In-vitro Transposition and Vaccine Development 
The underlying goal in the present study, with implications to human and 
ruminant health, is the exploration of virB1-mediated Brucella attenuation in the 
construction of a Brucella vaccine.  Studies toward the discovery of candidates for an 
effective yet safe Brucella vaccine have dominated Brucella-related literature over the 
past 25 years.  The problem has been approached by several angles, including 
investigations into live-vaccines, whole-killed vaccines, soluble extracts containing LPS 
and outer membrane proteins as vaccines, and increasing the population frequency of 
genes in the host responsible for natural resistance to brucellosis (Huddleson 1947b; 
Davies, Cocks et al. 1980; Dubray and Bezard 1980; Frenchick et al. 1985; FAO/WHO 
1986; Nicoletti 1990; Price, Templeton et al. 1990; Zhan and Kelso 1993; Bowden et al. 
1995; Drazek et al. 1995; Zhan and Cheers 1998).  Although currently there is no safe 
human vaccine, several exist for use in ruminants and small mammals, such as B. 
melitensis Rev.1, B. abortus strain 19 and B. suis strain 2 (FAO/WHO 1986).    
Lately, a promising method for vaccine development has been the creation of live, 
attenuated Brucella strains of low virulence by the inactivation of genes important for 
pathogenicity or survival.  Three difficult hurdles on this track have been:  1) The 
identification and inactivation of a gene or genes which decrease or eliminate Brucella 
virulence enabling the host to produce antibodies while still effectively clearing or 
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reducing the number of bacteria, 2) keeping a high level of humoral immunity towards 
brucellae over a long period of time, and 3) developing a vaccine which, even if not 
intended for human use, is safe for man.   
The current study focuses on part of the first hurdle to vaccine development, 
efficient inactivation of a virulence gene or genes.  Based on the present set of 
experiments, successful null mutations can be created in different Brucella species using 
a Tn7-based, in-vitro mutagenesis system.  While Tn5-based, in-vivo mutagenesis has 
been extensively carried out using Brucella, this is the first time, to the author’s 
knowledge, where a Tn7-based, in-vitro transposition system was employed with 
Brucella leading to mutant strains of B. melitensis 16M and B. abortus 2308 having 
attenuated virulence in the murine macrophage and mouse models.   
4.6 Advantages and Applications of Tn7-based Transposition 
Tn7 transposition of Brucella genes has several advantages over existing methods 
of in-vitro and in-vivo gene disruption.  As adapted by New England Biolabs, Tn7-based 
in-vitro transposition using the pGPS3 mutagensis system inserts a transposon randomly 
into the genome and does not require the presence of a specific restriction endonuclease 
site within the gene of interest.  Also, Tn7-based transposons exhibit target immunity, 
whereby only one insertion occurs over a distance of ~190 kilobases, which ensures 
single, rather than multiple gene knockouts in a cloned gene.  Tn7-based transposition 
can be used in-vitro, to target a specific gene cloned into a vector, while Tn5-based, in-
vivo systems cannot be targeted towards one particular gene.  In addition, in-vitro 
transposition is an extremely rapid method for Brucella gene knockout.  In-vivo, Tn5-
based mutagenesis systems require the screening of hundreds and possibly thousands of 
recombinants, which is exceedingly time consuming.  The entire process from 
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transposition to mutant strain confirmation, using targeted gene disruption via Tn7-based 
in-vitro transposition, can be performed in less than two weeks.  
The in-vitro transposition system described here, in combination with the recently 
published nucleotide sequence of B. melitensis 16M, has great potential value for the 
study of open reading frames with no assigned functions that make up 22% of the B. 
melitensis genome (DelVecchio et al. 2002).  Many regulatory and virulence-associated 
open reading frames, with homology in other bacterial systems, have also been identified 
within the Brucella genome.  Most of these loci of Brucella have never been studied in 
the laboratory, some examples include:  virF and virJ homologs, adhesins, invasins, 
incomplete sec-dependent, sec-independent, and flagellar type III and V secretion 
systems, thiamin synthesis genes, genes which code for heavy metal efflux pumps, 
enterobactin, BacA (a transport pathway gene), hemolysins, histidine kinase homologs, 
alkylation damage repair protein, stress-induced proteins similar to UspA of E. coli, a 
probable ABC transporter for copper uptake, and a heme catalase gene (DelVecchio et al. 
2002; Moreno and Moriyon 2002).  Creation of Brucella mutants lacking these genes, 
pathways or open reading frames could be swiftly accomplished with Tn7-based in-vitro 
transposition as it is described in this study.  Additionally, in-vitro transposition can 
accomplish multiple Brucella gene knockouts in the same organism through the use of 
different antibiotic resistance cassettes.  Possible targets could include inactivation of a 
putative or known pathway, such as lipid IV biosynthesis, at several important catalytic 
steps instead of one, or mutation of several outer membrane proteins at the same time.   
In a further assessment of this in-vitro transposition system and to examine virB1 
for vaccine potential, the laboratory of Dr. Philip Elzer at Louisiana State University is 
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currently evaluating the efficacy of BM29-106 in the natural host of B. melitensis, the 
goat.   
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